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In vitro production of erythrocytes in physiologic numbers from human induced 
pluripotent stem cells (hiPSCs) holds great promise for improved transfusion medicine 
and novel cell therapies. However, large-scale production of hiPSCs and their progeny by 
robust and economic methods has been one of the major challenges for translational 
realization of hiPSC technology.  
First, this thesis demonstrates a scalable culture system for hiPSC expansion using 
the E8 chemically defined and xeno-free medium under either adherent or suspension 
conditions. To optimize suspension conditions guided by a computational simulation, we 
developed a method to efficiently expand hiPSCs as undifferentiated aggregates in 
spinner flasks. Serial passaging of two different hiPSC lines in the spinner flasks using 
the E8 medium for more than 10 passages preserved their normal karyotype and 
pluripotency. Second, an optimized differentiation medium was developed for robust and 
consistent production of hematopoietic stem and progenitor cells (HSPCs) and progeny 
erythrocytes from hiPSCs, minimizing risk and variation due to the animal-derived 
products in cell cultures. Several crucial reagents were evaluated and replaced with 
regulatory-approved pharmacological reagents, such as Romiplostium, to establish a 
feeder-free and xeno-free condition, in which all the animal-derived products were 
eliminated. Erythrocytes from either the corrected or its parental (uncorrected) iPSC line 
were generated with similar efficiencies, showing enucleation and hemoglobin 
expression. Finally, a strategy for scalable generation of HSPCs from hiPSCs and 
subsequent erythrocytes specification was established, by using stepwise cell culture 
iii 
 
conditions and by integrating spinner flasks and rocker platform. This system supported 
robust and reproducible definitive hematopoietic differentiation of multiple hiPSC lines. 
An ultra-high yield of up to 4×109 CD235a+ erythrocytes at >98% purity was achieved 
when using a 1-liter spinner flask for suspension culture. Erythrocytes generated from 
this system can reach a mature stage with red blood cell (RBC) characteristics of 
enucleation, β-globin protein expression and oxygen-binding ability.  
In conclusion, this thesis demonstrates a xeno-free and cGMP-compliant system that 
provides the opportunity to produce clinical-grade erythrocytes from hiPSCs in a large-
scale bioprocess. Therefore, this study is a significant step towards the goal of large-scale 
generation of RBCs for therapeutic purposes. 
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1.1 Scalable expansion of human pluripotent stem cells 
Human pluripotent stem cells (hPSCs), including human embryonic stem cells 
(hESCs) and human induced pluripotent stem cells (hiPSCs), are capable of not only 
indefinitely self-renewing but also differentiating into any mature cell type of the body. 
Thus, hPSCs hold great promise for revolutionizing regenerative medicine, disease 
modeling, and drug discovery. In the past several years, researchers have been inspired 
by the development of techniques for the derivation, expansion, and differentiation of 
hPSCs, as well as by the ever-increasing knowledge about their genetic, epigenetic, and 
functional properties. In spite of unsolved problems, these developments have moved us 
significantly closer to the ultimate goal of hPSC-based cell therapies. Manufacturing an 
hPSC-based product will comprise a number of complex steps, including cell isolation, 
initial purification and expansion, derivation of hPSC lines, creation of master and 
working cell banks, large-scale expansion, differentiation, purification, storage, 
distribution, and transportation of the final product, in addition to intensive quality 
control and testing for each step. This chapter focuses on one crucial hurdle impeding the 
realization of late-stage clinical trials and commercialization of hPSC regenerative 
medicine — the efficient and scalable expansion of hPSCs under clinically compliant 





requirements, the development of culture media and substrates for expanding hPSCs, the 
demands and current situation of large-scale production. 
1.2 Human pluripotent stem cells  
First derived from the inner cell mass of the human blastocyst by James Thomson 
and colleagues in 1998 [1], hundreds of hESC lines have been generated and thoroughly 
studied. According to the NIH Human Embryonic Stem Cell Registry, the NIH has 
approved the registration of a total of 210 hESC lines, 49 of which contain disease-
specific mutations. These hESC lines offer precious opportunities for the study of early 
human development, stem-cell biology, in vitro differentiation, and tissue formation. 
However, the derivation of hESCs requires the destruction of human embryos, which has 
raised an ethical controversy and led to stringent legal restrictions in the United States 
[2]. The limited sources of federal funding and the paucity of hESC lines representative 
of specific diseases, especially for somatic or aging-dependent diseases, have narrowed 
down the potential applications of hESCs in disease modeling, pathology, and cell 
therapy. Moreover, the allogeneic nature of hESC therapies requires that the donor and 
the patient have matching human leukocyte antigen (HLA) types to reduce immune 
rejections, further increasing the limitations. 
Scientists have actively sought to use somatic-cell nuclear transfer (SCNT) 
technology to generate personalized hPSCs for patient-specific research, especially after 
the report of cloning of Dolly the sheep in 1997 [3]. Noggle et al. generated a blastocyst 
by transferring the genome of an adult somatic cell into an oocyte with an intact nucleus, 





more generally, the limited availability of human oocytes have kept this technology from 
practical and widespread implementation. Very recently, Tachibana et al. reported rapid 
derivation of hESC lines from blastocysts they generated by optimized SCNT protocol 
that allowed to remove oocyte nucleus and to develop normal diploid blastocysts [5]. In 
addition to ethic controversy and practical difficulty to obtain sufficient eggs from female 
donors, the complexity and low efficiency of current SCNT technique will unlikely 
become a steady technology to generate autologous hPSCs in the near future. 
After the momentous 2006 announcement that induced pluripotent stem cells 
(iPSCs) had been derived from mouse fibroblasts [6], Yamanaka and colleagues reported 
altering human cell fates to generate hiPSCs from human fibroblasts by expression with 
only four transcription factor genes [7]. Thomson and colleagues achieved the same 
marvel by using slightly different 4 factors at the same time [8]. This revolutionary 
finding stimulated many follow-up studies and opened up a completely new field — the 
generation and use of hiPSCs in a wide variety of human biology and disease research 
[9]. In addition to skin fibroblasts, mononuclear cells in the peripheral blood of human 
adults were also successfully used to generate integration-free hiPSCs, offering an easier 
way to avoid skin biopsy operations to get donor samples from probably the most 
commonly accessible cell sources in clinic [10-13].  
Research showed that human iPSCs share equivalent phenotypical and functional 
properties with hESCs. They have identical morphologies; they grow indefinitely and 
exhibit telomerase activities; they can be positively stained for alkaline phosphatase 
activity; they express comparable levels of such pluripotency genes as OCT4, SOX2, and 





SSEA3, and SSEA4; and they can differentiate into cells from all three embryonic germ 
layers in vitro after induction.  Their developmental pluripotency is also validated by 
their ability to form teratoma (in immune-deficient mice), a benign tumor consisting of 
cells of all the 3 embryonic germ layers that was uniquely formed by pluripotent cells. 
Recent studies of genome-wide gene expression and DNA methylation have revealed 
subtle but detectable differences between hiPSCs and hESCs (although variations 
between hESC or iPSC lines also exist) [14] Gene expression and DNA methylation 
revealed the epigenetic markers present in the parental somatic cells were not completed 
erased in derived iPSCs and remaining ones (i.e., the so-called epigenetic memory) do 
exist although diminish with serial passages. Evidence that hiPSC lines differentiated 
more efficiently into the cell types from which they were derived, or less to another cell 
type also existed [15, 16]; this, from a positive point of view, could prove beneficial for 
providing more efficient differentiation on demand even than from hESCs. 
Although many unknowns remain in the emerging field of hPSC research, 
pioneers have already cautiously started to explore potential clinical applications using 
hPSCs. One booming field is hPSC-based tissue engineering. Using hPSC-derived cells, 
researchers have generated fully or partially functional human tissues like those from 
liver, bone, neuron, blood vessel, heart, eye, etc [17-23]. These studies provided proof-of-
concept for potential cellular therapies, and yet were still at the starting line of the long 
journey towards realistic clinical implement. 





In order to examine the clinically compliant settings for hPSC expansion, we can 
learn more from approved clinical trials. In 2009, the U.S. Food and Drug Administration 
(FDA) approved the world’s first human clinical trial of hESC-based therapy by Geron 
Corporation for treating spinal cord injuries. In this study, hESCs were differentiated into 
oligodendrocyte progenitor cells (OPCs). The patients, all of whom had severe spinal 
cord injuries, each received an injection of approximately 1.5 million hESC-derived 
OPCs in order to repair the myelin insulation around their nerve cells and restore spinal 
cord functions [24]. However, the company stopped this trial abruptly in 2012 [25]. 
Although the exact reason(s) unclear, there were at least two possibilities: first, the cell 
dosage used in the study might not have been large enough to affect the patients’ injured 
spinal cords; second, the process of expansion and differentiation of hESCs under clinical 
compliant settings was complex, causing dosage or unacceptable pricing problems. 
Currently, only three ongoing clinical trials of hPSC therapy have gained approval by 
FDA. All three of these phase I/II trials led by Advanced Cell Technology (ACT) Inc. are 
based on transplanting hESC-derived retinal pigment epithelial (RPE) cells for an eye 
disease.  
1.3.1 Ongoing clinical trials of hESC therapies 
RPE cells are critical for supporting photoreceptors in the human retina. Diseases 
such as advanced dry age-related macular degeneration (AMD) and Stargardt’s macular 
dystrophy (SMD) can destroy RPE cells, causing vision impairment and even blindness. 
The researchers attempted to replace degenerate RPE cells and restore visual function by 





their retinal injection [26]. The phase I trials sought to study the efficacy, safety, and 
tolerability of this therapeutic approach to treating AMD and SMD. In their studies, the 
transplantation of 50,000 to 200,000 hESC-derived RPE cells constituted one dosage. 
Data gathered halfway through the clinical trials showed that patients having either of 
these two diseases experienced improved vision [27]. Because this treatment would work 
with small dosage sizes and because the final RPE cell product for implantation did not 
require the use of additional materials, such as scaffolds or nanoparticles, which may lead 
to complicated categories (combinations of Tissue, Device, and Biologic) that usually 
trigger slow regulatory process [28, 29], the FDA found it suitable to approve this hESC-
based therapy ahead of other potential hPSC therapies. More recently, an institutional 
review board in Japan granted conditional approval of a planed clinical trial using RPE 
cells derived from hiPSCs, which is awaiting final approval from the Japanese 
government [30]. 
1.3.2 Current applications of hiPSCs 
With concern about safety issues, research exploiting the unique clinical 
properties of hiPSCs has focused mainly on establishing disease models for the study of 
pathology, toxicology, diagnosis, and drug screening [31], giving an advantage to broad 
patient-specific cell sources [32-34]. Another potential clinical application of hiPSCs, 
gene-correction based stem cell therapy [35], would use the strategy of deriving an iPSC 
line from a patient with a disease caused by a genetic defect such as sickle cell disease 
[36]. Such diseases could then be treated by gene correction using zinc finger nuclease 





reported CRISPR/Cas9 system [39] to repair the endogenic pathogenic mutations, after 
which they repaired genes would be expanded and differentiated into desired cell types 
for pathology study or transplantation purpose. For additional reading, please refer to 
thorough reviews about the use of hiPSCs in disease modeling and gene therapies [9, 40] 
by Robinton et al. and Merkle et al. To keep its focus on the expansion of hPSCs, this 
review will consider several prominent aspects for developing bioprocess of hPSC 
expansion. 
1.3.3 Xeno-free conditions and chemically defined reagents 
According to the Guidelines for the Clinical Translation of Stem Cells (available 
at http://www.isscr.org/home/publications/ClinTransGuide) developed by the 
International Society for Stem Cell Research (ISSCR) [41], although the inclusion of 
animal materials in the hPSC manufacturing process does not prohibit using the cells in 
humans, the processes and products must undergo additional tests to exclude the 
transmission of animal pathogens, antigens, and mycoplasma into the products. This will 
increase the cost and time for clinical grade manufacture. One option is to find alternative 
components of human origin to avoid xenogeneic contamination. In any case, whether the 
products come from animal or human sources, they remain undefined because they 
contain a complex mixture of growth factors, hormones, extracellular matrix proteins, 
and many other functional and nonfunctional molecules that cannot be completely 
determined and excluded. They also have a high risk of exposure to viral contaminants, 
which will necessitate complex virus detection screening of the products [42, 43]. 





to-batch variations, reducing the reproducibility and reliability of therapeutic cell 
products [44]. The preparation of feeder cells is also time-consuming and requires 
irradiation equipment and qualified personnel. All of these factors make it more practical 
and economical to use, where possible, chemically defined components that can reduce 
the variance and the uncertainty of generating cell-based products with consistent quality. 
1.3.4  Current good manufacturing practices (cGMP) 
The term cGMP is a “quality management system” for manufacturing and testing 
products intended for human use, assuring that they are “safe, pure, and effective” 
(http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm
064971.htm, FDA cGMP guidelines). All clinical trials in the U.S. must manufacture any 
cell products under FDA cGMP guidelines (Code 21 CFR 210–211, 312, 600, and 1271). 
Especially, human cells, tissues, and cellular- and tissue-based products (HCT/Ps) must 
comply with the current good tissue practices (cGTP) rules (Code 21 CFR 1271). 
Equivalent regulatory rules have also been established in Europe (EU Directive 
2003/94/EC) and many other countries and regions internationally (ICHQ7). Thus, cGMP 
compatibility must receive specific consideration during the development of hPSC 
culture systems for clinical use. The manufacturing processes and analytical methods 
should be carefully developed, fully controlled, and exhaustively documented. This 
comprises many elements, such as valid protocols, control of work flow and cross-
contamination, clean room operation, monitoring and control of critical environmental 
parameters (including temperature, O2, and CO2), and so on. The cGMP also requires the 





training of staff and technicians. Meticulous documentation management is extremely 
important for a cGMP process. All of these rules aim to avoid any possible 
contaminations and operational errors throughout the process and to retain the ability, for 
any problem that might occur, to trace its origin, correct the problem, and identify all 
possible impacts. 
Many companies and research institutes have established cGMP-compliant hPSC 
culture facilities and relevant protocols, mainly for the purpose of cell banking, including 
the WiCell Research Institute (http://www.wicell.org), Cellular Dynamics International 
(http://www.cellulardynamics.com), the City of Hope National Medical Center [45], 
Upstate Stem Cell cGMP Facilities at the University of Rochester Medical Center 
(http://www.urmc.rochester.edu/upstate-stem-cell-facility), etc. These facilities provide 
cGMP-compliant services for all hPSC derivation, expansion, and differentiation for cell 
banking and clinical trials. 
1.3.5 Demand of robust and scalable cultivation of hPSCs 
Thus far, clinical trials with hPSCs have been limited to therapies that need only 
small dosages of cells. Apparently, the size of hPSC dosage required to treat a certain 
disease is a critical considerations for decision-makers choosing which disease to 
investigate using stem cell therapy. Although the desired scale of hPSC expansion in 
autologous therapies may be much smaller than in allogeneic therapies, autologous 
treatments for many other diseases and injuries still demand what are estimated to be 
large quantities of hPSCs and/or their progenies to replace cells that do not regenerate. 





enough islets for the transplantation treatment of type I diabetes [46]; an optimized dose 
for performing hematopoietic stem cell (HSC) transplantation for a 70-kg adult patient 
contains from 4.2×108 to 5.6×108 CD34+ cells [47]; an engineered myocardial tissue 
should contain at least 1 to 2 ×109 to repair the damaged heart from a typical myocardial 
infarction [48]; a minimum number of 106 surviving tyrosine hydroxylase-
immunopositive neurons per side of the brain were necessary to have a positive clinic 
response for Parkinson’s disease treatment [49], which may require 109 to 1010 hPSCs 
considering the low differentiation and survival rate [50]. 
Moreover, even for the small-dosage therapies, such as the clinical trials 
mentioned above for treating AMD, moving to phase II/III clinical trials can require the 
participation of hundreds to thousands of patients in multiple clinical sites, necessitating 
the development of batch cultures with the capacity to produce several hundred dosages, 
not to mention the requirements for the bulk manufacture of final commercial products. 
Clinical trials for these applications can only receive approval once the difficult problems 
in efficient (timely and economical) and scalable expansion and differentiation of hPSCs 
and their progenies for therapeutic purposes. 
An optimal culture system would support the self-renewal of undifferentiated 
hPSCs with minimal selective pressure. Culturing cells under stressful conditions or for 
long periods may cause DNA deletions, rearrangements, and other genetic or epigenetic 
abnormalities that can lead to pathogenic disasters like cancer. Thus, hPSCs should be 
expanded vigorously for a minimized period and finally reached the desired quantity in 
one batch of production with high capacity. For a rough estimation as an example, a good 





clinically relevant quantity of 1012 cells within 20 to 30 days in approximately 5-10 
passages, considering the current status of development in this field.  
1.4 The evolution of feeder cells and substrates 
One intrinsic feature of hPSCs is that the cells require tight cell-to-cell contact for 
survival and proliferation [51, 52]. To provide the necessary signals and a substrate for 
cells to attach to, researchers have developed various feeder cells or substrate materials. 
Conventionally, mouse embryonic fibroblast (MEF) feeder cells were used to support the 
derivation and self-renewal of hPSCs in a two-dimensional (2-D) adhesion culture. For 
example, the hESCs used in the current RPE clinical trials were cultured on MEF feeder 
cells [26]. To eliminate xenogeneic contaminations, various types of human feeder cells 
from allogeneic muscle, skin, marrow, and endometrial cells, etc. [53-56], as well as from 
autogenic hESC-derived fibroblasts [57, 58], were developed in the early 2000s. Some of 
these new feeder cells also proved capable of supporting the derivation of new hPSC 
lines [54, 55, 58]. 
Since the first study, published more than a decade ago in 2001 [59], Matrigel 
(BD Biosciences) has been widely used as a substrate for the feeder-free adhesion culture 
of hPSCs. Matrigel -- a mixture of extracellular matrix materials extracted from 
Engelbreth-Holm-Swarm (EHS) mouse sarcoma cells, contain (approximately) 60% 
laminin, 30% collagen IV, 8% entactin, growth factors and indeterminate components 
(http://www.bdbiosciences.com/documents/BD_CellCulture_Matrigel_FAQ.pdf). It was 
established in the 1980s [60] and originally used for promoting differentiation and the 





used feeder-free substrate for 2-D and 3-D cell cultures. A similar product, Geltrex 
(Invitrogen) is also commercially available. However, beyond being xenogeneic, both of 
these materials suffer from lot-to-lot inconsistency, uncertainty of stable composition, 
risk of viral contamination, and inconvenient temperature sensitivity; all of these factors 
make them problematic for clinical grade manufacturing. 
To address these concerns, many researchers have focused their efforts on 
developing defined, xeno-free substrates that support the derivation and expansion of 
hPSCs. The primary candidates were individual or simple mixtures of purified 
extracellular matrix (ECM) proteins from Matrigel. Initial studies showed that purified 
laminin could support the growth of undifferentiated hESCs, while culturing hESCs on 
fibronectin- or collagen IV-coated surfaces was not promising [59]. Thomson et al. made 
a breakthrough, finding that a combination of collagen IV, fibronectin, laminin, and 
vitronectin can replace Matrigel to derive and expand hESCs in defined conditions [62]. 
Purified laminin from human placentas was proved sufficient for long-term maintenance 
of hESCs in media containing activin A [63]. Recently, further studies have reported on 
the improvements to laminin-based substrates and the related mechanisms [64-66]. 
Miyazaki and colleagues demonstrated that recombinant human laminin -- specifically 
the isoforms laminin-511, laminin-332, and laminin-111 -- support the attachment and 
long-term self-renewal of hPSCs in an undifferentiated state [64, 66]. These studies found 
the binding and signaling activity of the ECM through the major cell surface integrin 
receptor, α6β1, critical to interactions between the cell and the ECM. By keeping the 
essential binding sites of integrin α6β1, the truncated laminin fragments LM511-E8 and 





Recombinant human E-cadherin, which is recognized by integrin αEβ7 [67] and α2β1 
[68], has also exhibited the ability to act as an equivalent alternative to Matrigel.[69] 
Human fibronectin, which binds to integrin α5β1 and αVβ3 [70], was shown to support 
hESC expansion in a serum-free medium [71]. Another ECM component, vitronectin, 
was used to replace Matrigel, supporting the attachment and proliferation of hPSCs by 
mainly binding to integrin αVβ5 [72]. Chen et al. enhanced the attachment and survival 
of hPSCs on vitronectin-coated surfaces by cutting off the N-terminal and/or C-terminal 
fragments from full-length vitronectin [73]. These recombinant human ECM-based 
substrates offered significant improvements in establishing defined and xeno-free culture 
conditions for adhesion cultures of hPSCs under clinically compliant settings. Most of 
them were successfully transferred into commercially available products, such as 
CELLstart (Invitrogen), Laminin-511, and Laminin-521 (BioLamina); and Vitronectin 
XF (STEMCELL Technologies). Furthermore, the development of truncated protein 
substrates can not only offers improvements of the supportive effects in culture, but also 
enhances the yield and simplifies the procedure of production and purification of large 
recombinant proteins, providing the sort of economical benefit that has become one of the 
major concerns in the production of therapeutic applications [65, 73]. 
An extreme condition for truncated ECM substrates is to cut off most of the 
protein, keeping only a small peptide sequence of the active domain. Polymers, such as 
acrylate [74], or self-assembled molecules, such as alkanethiol [75], were arranged on the 
tissue culture surface to form a monolayer. Such peptides can be easily conjugated on a 
synthesized acrylate or alkanethiol surface during manufacturing to avoid the coating 





supported the growth of hESCs using an alkanethiol array [76]. Peptides originated from 
bone sialoprotein [74], vitronectin [74, 75], and laminin (such as Synthemax from 
Corning) [74] also proved capable of maintaining long-term undifferentiated cultures of 
hESCs. These peptides allow cells to attach and spread by binding to the 
glycosaminoglycans or integrins on the cell surface. However, the high price of peptide 
synthesis and the difficulty of bulk sterilization by gamma radiation due to degradation of 
the peptide remain the major hurdles to broad application of this technology. To make 
economical and ready-to-use culture surface, fully synthetic plastic surfaces without 
peptide fragments were recently studied [77-81]. Among all reported synthetic surfaces, 
poly[2-(methacryloyloxy)ethyl dimethyl-(3-sulfopropyl)ammonium hydroxide] 
(PMEDSAH) [79] and aminopropylmethacrylamide (APMAAm) [81] exhibited the best 
results, supporting robust and long-term expansion of multiple hPSC lines without 
compromising pluripotency or inducing abnormal karyotypes. Although how they do so 
remains not fully understood, both mechanical (including stiffness, wettability, and 
rigidity) and chemical properties of synthetic surfaces influenced cell attachment and 
proliferation by mimicking the biological microenvironment as other ECM substrates. 
For additional reading, please see an updated review [82] by Villa-Diaz et al. 
Appropriately treating the polystyrene surface with ultraviolet light and then coating with 
serum or vitronectin was also showed to improve hPSC compatibility [83]. 
Synthetic surfaces are suitable for large-scale robotic adhesion cultures because 
they eliminate the need for the coating procedure and allow storage and handling at room 
temperature. Furthermore, the compatibility with sterilization techniques used in bulk 





making ready-to-use products. Generally, substrates or surfaces containing protein or 
peptide components are not suitable for large-scale sterilization by γ-radiation due to the 
possible denaturation or degradation of these components [84]. The radiation may also 
affect the physical and chemical properties of the synthetic or the plastic surface. 
Therefore, the surfaces that have been proven to be capable for bulk sterilization, such as 
PMEDSAH, facilitate using cGMP in the production of commercial disposable vessels 
for large-scale expansion of clinical grade hPSCs. 
1.5 The evolution of culture media for hPSC expansion 
Strictly speaking, a discussion of feeder cells and substrates should also consider 
the corresponding culture medium as a system. The culture media for hPSCs have also 
evolved rapidly in recent years. Initially, hESCs were derived and cultured in a basal 
medium substituted with a serum or serum replacement, such as KnockOut Serum 
Replacement (Invitrogen), N2 supplement, or B-27 supplement (Invitrogen), which 
mainly contain human or animal serum albumin combined with various cytokines and 
growth factors either on feeder cells or on Matrigel [1, 7, 59]. At the same time, 
researches using feeder-free cultures often used media conditioned with feeder cells (i.e., 
conditioned media, or CM), which typically had serum replacement added to it before its 
incubation with feeder cells and the many undefined factors that they secreted. For a long 
time, MEF-CM was considered the gold standard for feeder-free expansion of hPSCs and 
was usually used as a baseline for comparison during the development of hPSC culture 
media. 
Over the past decade, to develop fully defined media without any unknown 





variety of formulas [62, 71, 73, 85-93]. In these studies, both fibroblast growth factor  2 
(FGF2) and the TGF/Activin/Nodal pathways appeared to be indispensable for the stable 
self-renewal of undifferentiated hPSCs. Some other cytokines could also help to maintain 
the pluripotency of hPSCs by activating similar pathways, such as Smad2/3, AKT and 
ERK1/2 [94]. Oh’s review comprehensively summarizes the mainstream evolution of 
serum-free medium [94]. Table 1-1 provides an updated summary of the media and 
culture conditions with regard to clinically compliant settings. Among these formulations, 
mTeSR1 (STEMCELL Technologies) and StemPro (Invitrogen) -- based on two 
publications in 2006 [62] and 2007 [89], respectively -- constituted significant milestones 
in the exploration of defined media. In 2010, the International Stem Cell Initiative 
Consortium performed an exhaustive study that documented the side-by-side validation 
of eight defined media [95]. Surprisingly, only mTeSR1 and StemPro media supported 
the attachment and undifferentiated expansion of most of the twelve different hESC lines 
tested during the ten-week test period in four different labs internationally. In other media 
tested, the cells either died due to low attachment or underwent progressive 
differentiation on Geltex or Matrigel [95]. Another side-by-side evaluation reported in 
2010 introduced a comparison of the three most popular feeder-free culture systems: 
mTeSR1-Matrigel, StemPro-CELLStart and mTeSR1-vitronectin [96]. Many other 
individual studies also used mTeSR1 and StemPro as standard serum-free media on 
different xeno-free substrates (Table 1-1). However, both of these media contain bovine 













































































































































































































































































































































































































































liquid components that are not fully defined. A xeno-free alternative for mTeSR1, which 
replaces BSA with human serum albumin, is also commercially available (TeSR2, 
STEMCELL Technologies), but its undefined nature and high price are still major 
drawbacks for clinical applications. Some studies have also used NutriStem XF/FF 
medium (Stemgent) as a xeno-free and feeder-free culture medium for hPSCs on Matrigel 
to remove MEF before other experiments, such as gene targeting [37, 97]. These studies 
observed the preservation of marker expression and differentiation potential, but no 
systematic comparative study has reported an examination of the long-term culture of 
hPSCs with this media. 
Impressively, Chen et al. recently reported a further refinement that finally 
eliminated BSA from their previous TeSR formula [73]. When reconsidering the 
necessity of the medium components in TeSR by double knockout, they found that BSA 
was not necessary in the absence of β-mercaptoethanol, a biological antioxidant. After 
further filtration, they simplified the formula to just eight essential components, including 
DMEM/F12 basal medium; the result, called E8 medium, is xeno-free and chemically 
defined. Combined with this group’s separate finding that truncated vitronectin substrate 
supported the expansion of hPSCs, this system was shown to support the derivation and 
continuous culture of multiple hPSC lines with improved reprogramming efficiency, 
robust expansion (6 to 14 folds every 3 to 4 days), and well-kept pluripotency [73]. This 
low-protein medium (now commercially available as Essential 8 from Invitrogen and as 
TeSR-E8 from STEMCELL Technologies) has demonstrated reproducible and promising 
results when used with either Vitronectin XF or Matrigel in a number of studies [98]. The 





StemPro or mTeSR1, and even more dramatically by 50% compared to the xeno-free 
alternative TeSR2. 
Compared to CM-MEF conditions, hPSC cultures in many feeder-free systems 
showed significantly higher expansion rates, lower differentiation rates, and homogenous 
populations -- but with a simpler process. Normally by using these systems, about 5 to 15 
folds of expansion can be achieved from one passage period within 3 to 7 days, and the 
culture can keep more than 80 to 90 percent of the hPSCs with positive expression of 
markers for undifferentiated state and normal karyotype for more than 20 passages. More 
importantly, combining many of these media with xeno-free substrates produced efficient 
systems for deriving hESC and hiPSC lines, showing promise as initial steps towards the 
clinical grade production of hPSCs in adhesion cultures. 
1.6  Expanding hPSCs in suspension  
The strategy of rapidly expanding hPSCs in adhesion was criticized for its 
intrinsic lack of scalability. Although the capacity of an adhesion culture can increase 
linearly to a certain level by adding more flasks in an automated system, a suspension 
culture system using conventional stirred-tank bioreactors is still preferred for its well-
established geometric scalability and its compatibility with the online monitoring/control 
of temperature, O2, CO2, pH, glucose, lactate and biomass [99], especially at the pilot 
scale or larger. Along with the evolution of culture media and substrates, the past decade 
has seen significant progress in the culturing of hPSCs in suspension. Generally, 
researchers have developed two distinct types of suspension cultures: one based on 





1.6.1 Microcarrier-based suspension culture  
In making the transition from adhesion to suspension cultures, initial studies 
focused on growing hPSCs on microcarriers in a “pseudo-suspension” culture condition. 
Coating the microcarriers with feeder cells or the other substrates mentioned above, the 
studies demonstrated that microcarriers provided large surface areas that hPSCs could 
attach to for expansion in agitating vessels such as spinner flasks. The microcarriers 
examined so far are spherical or cylindrical particles ranging in size from 60 to 800 µm 
and made of polystyrene, dextran, cellulose, or glass with similar density as the media 
[100-109]. A conclusive review covering microcarrier-based hPSC cultures was recently 
published [25] by Chen et al. In most studies, hPSCs were cultured in media conditioned 
with MEF or human feeder cells. Thus, in Table 1-2, we highlight only the two studies 
that were targeting clinical use, avoiding conditioned media and feeder-coated 
microcarriers. Importantly, Oh et al. showed that microcarrier-based suspension cultures 
could offer high-yield expansion of hESCs, reaching a maximum cell density of 3.5 × 106 
cells ml-1 in a seven-day culture [104], as compared to 0.8 to 1.5 × 106 cells ml-1 in side-
by-side adhesion cultures on Matrigel. Such high-yield cultures are preferable to the 
large-scale production of cells, because of the high conversion efficiency of media and 
labor. The authors hypothesized that, in a stirred bioreactor, microcarriers provide a 
larger surface area and better O2 and nutrient transfer than adhesion cultures [104]. Heng 
et al. demonstrated the use of human laminin to coat microcarriers, followed by culturing 

























































































































































































































































































































































































































































































































































































   
   
   
   
   
   
   
   
   
   
   
   
   
  
   
    





































































































































































losing pluripotency and normal karyotype [109]. This remains the only reported study 
that has successfully cultured hPSCs on microcarriers coated with xeno-free substrate in a 
nonconditioned medium. Although the microcarrier-based suspension culture has been 
scaled up to working volumes of 150 ml in spinner flasks, the experiments revealed 
several shortcomings. Because hPSCs tended to stick together rather than evenly 
distribute on the microcarrier surface [25], heterogeneous clustering might occur during 
the culture process, which could induce unexpected differentiation and selection of 
genetically abnormal populations due to the stress created by insufficient transfer of 
nutrients and O2. Moreover, removing microcarriers at harvest required additional 
filtration that would be a cumbersome step for cGMP manufacturing. 
1.6.2 Aggregate-based suspension culture 
Inspired by the self-aggregation observed in the embryoid body (EB) 
differentiation of hESCs in suspension [117-120], researchers sought to establish carrier-
free suspension culture systems for expanding hPSCs (Table 1-3). Initially, they 
inoculated cells into suspension cultures as cell clumps, using mechanical or mild 
enzymatic passaging methods [121, 122], which resulted in relatively heterogeneous 
formations of cell aggregates and a reduced reproducibility. After the discovery of Rho-
associated coiled-coil kinase (ROCK) inhibitors (Y27632, HA-100, etc.) and their 
function of diminishing apoptosis and permitting the survival of dissociated hPSCs [51, 
123], several groups established suspension culture systems that, with the addition of 
ROCK inhibitors to the culture media, supported single-cell inoculation, uniform 





Zweigerdt et al. and Amit et al. reported detailed protocols for the adaptation and 
expansion of hPSCs in both static and dynamic suspension in a variety of vessel types 
[112, 113]. Recently, Olmer et al. reported a high-yield culture in a fully controlled 
bioreactor system. Up to 2 × 108 of hiPSCs were obtained from a working volume of 100 
ml in a single run of seven days [115]. Chen et al. moved one step forward to clinically 
compliant process showing long-term culture of hESCs in suspension with a calculated 
cumulative expansion of more than 1 × 1013-fold within 21 passages (about three 
months). That paper also demonstrated a complete strategy for hESC banking under 
cGMP conditions using 500 ml disposable spinner flasks to expand cells [116]. 
Furthermore, Steiner et al. also claimed a complete strategy to derive, expand, and 
differentiate hESC lines all in suspension conditions [125], making it possible to avoid 
any effects from feeder cells and substrates. 
The key to efficient expansion in aggregate-based suspension cultures is to keep 
homogeneous aggregate formation to an appropriate size that allows the effective 
diffusion of nutrients. This can be accomplished by improving media formulation and 
passaging methods to enhance cell viability, as well as by designing bioreactors with 
optimized hydrodynamic properties that generate mild but sufficient shear stress in an 
evenly distributed velocity field. Different hPSC lines have varying adaptability to shear 
stress [112], which may also constitute a limitation for universal applications. 
Furthermore, well-controlled one-direction shear flow showed enhancive effect on the 
hematopoietic and endothelial differentiation of PSCs in adhesion [126, 127]. However, 
the shear force on the cell surface in the suspension culture system is uncontrolled and 





cell aggregate. The effect of this inconstant shear stress to in vitro cell differentiation has 
not been clearly understood. Thus, optimization of the operation, including agitating 
speed, seeding density, media change, and split interval, is a necessary step for each 
particular hPSC line. 
1.7 Culture scales and equipment  
The scale of hPSC expansion for clinical use should be determined by the 
demands and specifications of individual therapies. The decision should consider the 
potential market, cells/dose, doses/year, lots/year, doses/lot and, eventually, 
determination of the total manufacturing requirement [128].  
Potential allogeneic therapies using hPSCs usually aim to provide cell products 
derived from a single donor to many other patients. Accordingly, the culture scale for this 
type of therapy could run from tens to hundreds of liters in order to be cost-effective. For 
hPSC cultures at this level, only a large-scale stirred-tank bioreactor system combined 
with aggregate-based suspension cultures might meet the requirement, although its 
development would remain very challenging.  
In contrast, the strategy of autogenic therapies relies on providing cell products to 
treat only the patient who donated the parental cells, which adheres more closely to the 
principle of hiPSC therapies. Since the cultured products are for a single patient, a 
relatively small-scale hPSC culture should be adequate, as long as efficient differentiation 
and downstream processes are well established. For this purpose, the current level of 
development of highly efficient adhesion cultures might suffice, when combined with 





(Thermo Scientific Nunc), to obtain the needed cell dosages. A fully controlled, compact 
and closed planar culture system (Integrity Xpansion, ATMI) has also become 
commercially available. Achieving productions of hPSCs in large lot-size using adhesion 
cultures could also occur with the assistance of robotics technology to facilitate the 
handling of many culture flasks [129]. Successful studies have reported automated hESC 
adhesion cultures using the CompacT SelecT (TAP Biosystems) and the 3D Cellhost 
(Hamilton) systems [130, 131]. The CompacT SelecT system can handle an estimated 90 
T175 flasks per run, providing 15,750 cm2 of surface area that can yield approximately 3 
× 109 hPSCs in a single three-day culture in feeder-free conditions. For comparison, the 
largest volume used in current studies on suspension cultures of hPSCs was 250 ml. A 
three- to six-day culture can harvest approximately 2 × 106 cells ml-1, making a total yield 
of 2 × 109 for four parallel vessels in one regular size CO2 incubator. It should not be 
difficult to scale up to 500 ml in a 1-liter spinner flask, due to the compatible platform 
and bioreactor design. Comprehensive reviews by dos Santos et al. [132] and Want et al. 
[99] include useful information about bioreactor design and case studies of scale 
determination for clinical-grade expansion of hPSCs. 
1.8 Hematopoietic differentiation and erythrocyte production from hiPSCs 
As an irreplaceable clinical practice in modern medicine, red blood cell (RBC) 
transfusion saves lives of patients suffering from severe blood lose or chronic anemia. 
For example, transfusion-dependent patients often receive two or more units of donated 
whole blood or isolated RBC concentrates (each unit contains ~2×1012 RBCs) every two 





several decades, accessibility and dependence on blood donation remain critical around 
the world. This is a particularly important issue for the patients who need RBCs of rare 
blood types, because of severe complications caused by mismatching transfusion or allo-
sensitized responses among chronically transfusion-dependent patients [133]. 
1.8.1 Erythrocyte generation from primary CD34+ cells 
A potential solution is to manufacture RBCs from hematopoietic stem and 
progenitor cells (HSPCs) that are isolated from patients themselves or donors with 
desirable blood types. As the main source of in vitro RBC generation, human HSPCs 
were harvested from mobilized peripheral blood [134], bone marrow [135, 136], cord 
blood (CB), and fetal liver [137]. CB CD34+ cells were intensively studied as a primary 
candidate due to their high content of HSPCs, easy accessibility, and the nature as an 
otherwise discarded medical waste [138-144]. Recently, mature RBCs that were 
generated ex vivo from CD34+ HSPCs were transfused into a volunteer to demonstrate in 
vivo safety [143], albeit at limited quantity (~4×1010 RBCs or ~2% of one transfusion 
unit).  One major challenge for clinical applications has been how to expand HSPCs 
extensively because committed erythroid progenitors have limited proliferative potential 
before differentiating into mature RBCs [145]. 
1.8.2 Erythrocyte generation from hPSCs 
In spite of worldwide study for over 20 years, CB CD34+ cells showed limited life 
span in vitro under current expansion conditions [145]. Instead, hPSCs provide realistic 
alternative choices for the ability of indefinite expansion and directed differentiation in 





and to adult), and functional oxygen carrying ability in hESC-derived RBCs [146-148]. 
Compared to the ethic and technical challenges of the generation of hESC lines, hiPSCs 
can be easily derived from donor somatic cells [149], providing a potentially unlimited 
source of any RBC type, especially universal donor type O Rhesus D-negative (O Rh-) 
and rare-phenotype matching RBCs, as well as pathogenic gene-corrected RBC for 
autologous transfusion therapies [150]. Convinced by the prove-of-concept to use hiPSCs 
as an alternative source of HSPCs and RBCs for their indefinite in vitro expansion and 
ease of genetic modification using rapidly evolving gene editing technologies, 
governments in UK (Medicines & Healthcare Products Regulatory Agency, 
https://www.gov.uk/government/organisations/medicines-and-healthcare-products-
regulatory-agency) and US (The American Recovery and Reinvestment Act, 
http://www.recovery.gov/arra/) are investing the generation of pathogen-free iPSCs from 
O Rh- donors for potential manufacture of universal donor RBCs. However, the 
efficiency of erythroid expansion was usually reported as 20 to 200-fold lower in hiPSC-
derived HSPCs than those from CB CD34+ [151].  
1.9 Scalability of the differentiation system 
Considering a manufacturing process required for clinical purposes, one has to 
implement a culture procedure with vessels that are suitable for large-scale cell culture 
and expansion. Most EB differentiation strategies involve separation of individual EBs 
using multi-well plates. They can only accommodate a pilot scale production in a scale-
out process by linearly increasing the number of culture vessels, which requires 





methods of forming EBs in suspension showed the capacity to adapt to vessels that were 
compliant with scale-up bioprocess and generate matured cells, such as cardiomyocytes, 
myeloid cells, and hepatocytes [152-156]. In these studies, spinner flasks and flat tissue 
culture flasks placed on a rocker were commonly used due to the scalability of directly 
transferring to well-established stirred tank bioreactors (up to 2000 L) and wave bag 
bioreactors (up to 1000 L), respectively. These bioreactor systems are widely utilized in 
industrial biotechnology for multi-parametric monitoring/control. However, this kind of a 
scalable system has not yet been established for the generation of human erythrocytes 
from hiPSCs. 
1.10 Clinical consideration for postexpansion downstream process 
After the differentiation process, the complete removal of undifferentiated hPSCs 
from the resultant product is strictly required to reduce the risk of tumor generation. For 
example, the clinical trial of RPE cells claimed that the product RPE dosage contained 
only 0.00008% parental hESCs. The cryopreservation method should also comply with 
the cGMP regulations, the expansion system, and the shipping and handling protocols. 
Hunt and Li et al. provided detailed reviews covering the development of 
cryopreservation for hPSCs under cGMP settings [157, 158]. 
Part of this section has been published in Ref. 233. 
1.11 Thesis Overview 
The ex vivo production of RBCs from hiPSCs holds great promise to potential 
clinical applications. However, it requires process that is compliant to large-scale 





chemical engineering, such as hydrodynamic analysis, mass transfer, bioreactor design 
and process optimization of physical cues, combined with optimization of biological 
cues, such as medium formulation and cytokine/growth factor studies, we can establish 
scalable systems for the expansion and erythrocyte production of hiPSCs. This thesis can 
be divided into three specific aims: 
Specific Aim 1: Establishing a scalable system for the long-term expansion of 
undifferentiated hiPSCs in suspension. 
Comparing to the reported systems for the expansion of hPSCs in suspension 
which used undefined media, here we utilized newly development E8 medium in glass-
ball type spinner flask to achieve long-term expansion of undifferentiated hiPSCs in 
xeno-free and chemically defined conditions. The study for this specific aim will be 
presented in Chapter 3. 
Specific Aim 2: Establishing an efficient and reproducible process for HSPC 
differentiation and erythrocyte production. 
We re-formulated the differentiation media using FDA-approved pharmacological 
reagents enhance the efficiency and reproducibility of the current hematopoietic 
differentiation process for the HSPC generation from hiPSCs. We also used human 
plasma to induce terminal maturation towards enucleated and β-hemoglobin expressing 
erythrocytes. The study for this specific aim will be presented in Chapter 4. 
Specific Aim 3: Improving the scalability of the differentiation system for 
erythrocyte production. 
The scalability limitation of the current EB differentiation system using 96-well 





improved the scalability using the combination of spinner flask and platform rocker. The 





2 Overview of Experimental Methods 
 
2.1  Approval of using hiPSCs and primary cells from anonymous donors 
The experiments using hiPSCs were approved by the Institutional Stem Cell 
Research Oversight (ISCRO) committee in the Johns Hopkins University. Use of 
anonymous human samples for laboratory research was approved by the Institutional 
Review Board of the Johns Hopkins University. 
2.2 Maintenance of hiPSCs in adhesion 
Human iPSC lines BC1, TNC1 and E2 were initially maintained on MEF feeders 
in standard ESC medium as previously described [11]. At passage 30-32, BC1 cells were 
dissociated using 0.5mM EDTA in calcium- and magnesium-free PBS [159], and directly 
adapted onto tissue culture plates coated with Matrigel (1.67 µg/cm2, BD) or truncated 
recombinant human vitronectin (VNT-N, 5 µg/cm2, Invitrogen) in E8 medium (home-
made as described by Chen et al. [73], or Essential 8 from Invitrogen) supplemented with 
10 µM ROCK inhibitor Y27632 (Stemgent) for 24 hours. Medium was changed daily. 
Cells were routinely passaged as small clumps using EDTA method [159] or as single 
cells using Accutase (Sigma-Aldrich) with the split ratio of 1:8 to 1:12 every 2 to 3 days 
after reaching 60% to 80% confluent. Cells were stained with 0.4% Trypan Blue, and the 






2.3 Flow cytometry analysis 
Single cell samples were prepared in 3×105 cells per aliquot. Undifferentiated 
iPSCs were stained with anti-TRA-1-60 (mouse IgM, 1:200, Millipore MAB4360), anti-
SSEA4 (mouse IgG3κ, 1:200, DSHB MC-813-70), anti-Oct4 (rabbit IgG, 1:100, Santa 
Cruz C-10), and anti- Nanog (rabbit IgG, 1:100, Peprotech P236) as primary antibodies, 
and Alexa Flour 488 (goat- anti-mouse IgM, goat-anti-mouse IgG3κ, or goat-anti-rabbit 
IgG, 1:400, Invitrogen) as secondary antibodies. The cells were fixed and penetrated by 
following the instruction of FIX & PERM® cell fixation & cell permeabilization kit 
(Invitrogen) for the staining of nuclear markers. For hematopoietic differentiation, 
conjugated anti-human CD34-APC, CD45-Alexa Flour 488 (1:20, BD), CD45-APC 
(Thermo Fisher Scientific), CD235a-FITC (Thermo Fisher Scientific), CD36-APC (BD 
Biosciences), Band3-FITC or Band3-APC (kindly provided by Dr. Xiuli An at New York 
Blood Center), CD49d-FITC (Miltenyi Biotec), CD71-PE (Thermo Fisher Scientific), 
CD14-FITC (Thermo Fisher Scientific), CD41-APC (Thermo Fisher Scientific), CD42a-
PE (Thermo Fisher Scientific), CD15-FITC (Thermo Fisher Scientific), CD33-PE 
(Thermo Fisher Scientific) were used. To analyze hemoglobin expression, cell stained 
with anti-β-globin-PE (Santa Cruz Biotechnology) and anti-fetal hemoglobin-FITC 
(Thermo Fisher Scientific) after fixation and permeabilization. To analyze enucleation, 
cells were co-stained with DRAQ5 (a cell permeable dye for DNA staining, Cell 
Signaling Technology). Isotype controls were set according to the antibodies. Before 
analysis by fluorescence-activated cell sorter, dead cells were stained by Via-Probe cell 
viability solution (BD Bioscience) and gated out in analysis to avoid unspecific staining. 





cell death detection kit fluorescein, Roche) was performed according to the 
manufacturer’s instructions. Negative and positive controls for TUNEL were set 
following the instructions of the kit. All samples were analyzed with FACSCalibur flow 
cytometer (BD Bioscience). At least 15,000 gated events were collected and analyzed 
using FlowJo X software.  
2.4 Immunofluorescent staining and fluorescent microscopy analysis 
Undifferentiated hiPSCs on Matrigel- or VNT-N-coated plates or spontaneously 
differentiated cells on gelatin-coated plates were prepared for immunofluorescence 
microscopy as described before [11]. For undifferentiated hiPSCs, anti-TRA-1-60 
(1:100), anti-SSEA4 (1:100), anti-Oct4 (1:50), and anti-Nanog (1:50) were used as 
primary antibodies. The corresponding secondary antibodies were Alexa Flour 555 (goat-
anti-mouse IgM, or goat-anti-mouse IgG,1:200, Invitrogen) and Alexa Flour 488 (goat-
anti-rabbit IgG, 1:200, Invitrogen), respectively. For spontaneous differentiation, anti-α-
fetoprotein (rabbit IgG, 1:500, DAKO), anti-CD31-PE (conjugated, 1:5, BD), anti-β-3-
tubulin (mouse IgG, 1:1000, Sigma T8660) were used, and Alexa Flour 555 (1:200) was 
stained for visualization. After wash, cells were stained for nucleus and mounted with 
ProLong Gold antifade reagent with DAPI (Invitrogen). 
Cells from terminal maturation day 6 (TM6) were incubated in terminal 
maturation medium with 5 µM Calcein AM (Thermo Fisher Scientific) for 1 hour in 37 
°C. After wash once with PBS, 1×104 cells were re-suspended in 100 µl PBS+1% FBS 





room temperature for 20 min. All fluorescent images were acquired using Eclipse 
TE2000-U microscope (Nikon). 
2.5 Cytospin and histological staining 
All single cells (6×104 - 9×104 cells per slide depend on cell size) were mounted 
on slides using Cytospin (Thermo Fisher Scientific) as per manufacturer’s instructions. 
Hema 3 kit (Thermo Fisher Scientific) was used as a Wright-Giemsa-like staining for cell 
morphology analysis.  
2.6 Colony-forming unit (CFU) assay 
Methylcellulose-based MethoCult Kit (STEMCELL Technologies) was used for 
hematopoietic CFU assay as per manufacturer’s instructions. Suspended cells (5,000 
cells) on EB day 13 to 14 were seeded into 35-mm dishes supplemented with 3U/ml 
erythropoietin (EPO). After 14 days of semi-liquid culture, colonies were scored 
according to the standards provided in the MethoCult protocol.  
2.7 Statistics 
All analysis of cell number, cell viability, EB size, and flow cytometry were collected 
from at least three independent experiments (n ≥ 3), and all measurements were done in 
duplicates or triplicates to avoid sampling error, if possible. Quantitative real-time 
polymer chain reaction (qRT-PCR) analysis was performed in two independent 
experiments with triplicate readings each. The unpaired two-tailed Student's t-test or two-
way analysis of variance (two-way ANOVA) followed by Bonferroni’s posttest was done 





respectively. Data are presented as mean ± SD if not specified. Significance level was 



















3 Scalable expansion of hiPSCs in the defined 
xeno-free E8 medium under adherent and 
suspension culture conditions  
 
Large-scale production of hiPSCs by robust and economic methods has been one 
of the major challenges for translational realization of hiPSC technology. Here we 
demonstrate a scalable culture system for hiPSC expansion using the E8 chemically 
defined and xeno-free medium under either adherent or suspension conditions. To 
optimize suspension conditions guided by a computational simulation, we developed a 
method to efficiently expand hiPSCs as undifferentiated aggregates in spinner flasks. 
Serial passaging of two different hiPSC lines in the spinner flasks using the E8 medium 
preserved their normal karyotype and expression of undifferentiated state markers of 
TRA-1-60, SSEA4, OCT4, and NANOG. The hiPSCs cultured in spinner flasks for more 
than 10 passages not only remained pluripotent as indicated by in vitro and in vivo assays, 
but also could be efficiently induced towards mesodermal and hematopoietic 
differentiation. Furthermore, we established a xeno-free protocol of single-cell 
cryopreservation and recovery for the scalable production of hiPSCs in spinner flasks. 
This system is the first to enable an efficient scale-up bioprocess in completely xeno-free 
condition for the expansion and cryopreservation of hiPSCs with the quantity and quality 






Human pluripotent stem cells (hPSCs), including human induce pluripotent stem 
cells (hiPSC) and human embryonic stem cells (hESCs) that can differentiate into any 
mature cell type of the body, hold great promise for revolutionizing regenerative 
medicine. Specifically, the integration-free reprogramming technologies, such as ones 
using plasmids, provide a feasible method to generate autologous and clinical-grade 
hiPSC lines for therapeutic applications under current good manufacture practice (cGMP) 
conditions. Patient-specific hiPSC lines derived from postnatal somatic cells [11-13], can 
not only be used to establish disease-specific models for pathological studies, but also 
exhibit vast potential in practical cellular therapies. These clinical applications require a 
large number of hiPSCs or their progenies. For example, an optimized dose was 
suggested to contain 4.2×108 to 5.6×108 CD34+ cells for hematopoietic stem cell (HSC) 
transplantation for a 70-kg adult patient [47]. Production of a clinically relevant quantity 
of hiPSCs and/or their progenies for specific applications, sometimes considered as ~1 to 
2 billion [122], in a chemically defined condition by robust, reproducible and economic 
methods remains a major challenge for advancing hiPSC technology from the bench to 
the clinic. 
Conventionally, hiPSCs are induced and expanded on feeder cells as adherent 
colonies in media containing sera or serum replacement containing human or animal 
serum albumin [160, 161]. The involvement of animal products or sera impedes these 
culture conditions to meet the strict requirement of clinical or pre-clinical utilization 
because of the uncertainty of complex components and the quality variance from batch to 





free chemically defined culture medium and substrates for adherent hiPSC culture have 
been developed [73, 85, 89, 162, 163]. However, these approaches involving adherent 
culture of hiPSCs in Petri dishes still raise a major hurdle of large scale and well-
controlled expansion for clinical use.  
Suspension culture for hiPSC expansion provides a feasible solution for its scale-
up capacity. After a Rho-associated-coiled-coil kinase (ROCK) inhibitor Y27632 was 
reported to permit the survival of dissociated hESCs when supplemented in the medium 
only on the first day of seeding [123], detailed protocols were established for the single-
cell inoculation and suspension culture of hPSCs as cell aggregates in a variety of vessel 
types [112, 113, 124]. Other studies have also reported successful suspension culture in 
spinner flasks in 100-ml vessels [110, 111, 114-116, 125, 164]. Despite the rapid 
development of hPSC suspension culture in these studies, most of the reproducible 
systems are based on commerciality available serum-free media, mTeSR or StemPro, 
which are complex and expensive. The unknown composition and high cost of these 
media pose a major concern for large-scale expansion.  
Chen et al. recently reported the development of a significantly improved hiPSC 
culture medium, E8, which contains only seven other completely defined and xeno-free 
components supplementing the standard DMEM/F-12 medium [73]. We did confirm that 
this significantly improved medium without the need to add BSA or human albumin 
supported the growth of multiple hiPSC lines under feeder-free conditions in adhesion.  
Based on this, we sought to test whether the significantly simplified E8 medium could 
support a robust and economic suspension culture system in a stirred bioreactor for large-





hiPSC lines, BC1 and TNC1, which were derived from leukocytes of either a healthy 
donor or a sickle cell disease patient using plasmid-based episomal vectors [11]. We 
began by evaluating the capacity of E8 medium to support the expansion of hiPSCs in 
static suspension cultures. We then optimized the operating protocol for direct adaptation 
and expansion of the hiPSCs in spinner flasks using computational simulation of the 
hydrodynamic properties and experimental tests. Furthermore, we tested serial passaging 
and differentiation potential of hiPSCs expanded in spinner flasks. Finally, xeno-free 
cryopreservation and recovery methods were established for hiPSCs cultured in the 
bioreactor. 
3.2 Materials and Methods 
3.2.1 Suspension culture of hiPSCs 
 BC1 and TNC1 were cultured in feeder-free adhesion culture for at least 5 
passages before transfer in suspension culture. Prior to the passage, hiPSCs were treated 
with Y27632 for 1 hour and dissociated with pre-warmed Accutase for 2 to 3 min in 
37°C. After gently pipetting, the single cell solution was diluted 1:10 with DMEM/F-12, 
and centrifuged at 200g or 5 min. Cells were resuspend by adding E8 medium with 10 
µM Y27632 and plated at density of 1.5×105 to 2.0×105 cells/ml in ultra-low attachment 
plates or seeded at 4×105 to 5×105 cells/ml. Daily medium change was performed by 
replacing 70% of the medium with fresh E8 medium without ROCK inhibitor. Cells were 
cultured in static condition or in spinner flasks (CELLSPIN system of 100 ml capacity 
with a single glass-ball stirring pendulum, Integra Bio-sciences) in standard 5% CO2 





3.2.2 Computational fluid dynamics (CFD) analysis of glass-ball spinner flasks 
The “Chemical engineering” module in COMSOL Multiphysics® 3.5 software 
was used to perform the numerical calculation of the velocity field and shear stress 
distribution in the spinner flask. A 3-dimentional (3D) “Rotating machinery” model was 
established following the user guide of the software to simulate the agitating effect of the 
glass-ball impeller. The geometry of the spinner flask was measured from the real object, 
and the total volume of the fluid body in the model was set as 45.6 ml or 639.6 ml for the 
simulation of 100-ml or 1-L spinner flask, respectively. The gap between the moving 
mesh coordinates and the fixed mesh coordinates was set to 0.02 mm. An automatic 
generated fine mesh divided the entire fluid body into >10, 000 elements. The velocity 
field was calculated following Navier-Stocks equation for incompressible fluid at steady 
state, neglecting gravity: 
𝜌(𝒖 ∙ ∇)𝒖 =   ∇ ∙ [−𝑝𝑰+   𝜇 ∇𝒖+ ∇𝒖 ! ]                              (Eq. 1) 
where r and m are the density and the dynamic viscosity of the fluid, respectively; 𝒖 is 
the vector of velocity in three directions; 𝑝 is pressure, and ∇ is the gradient operator. On 
a certain X-Y plate, the x-y component of the shear stress tensor was defined as: 





)                                              (Eq. 2) 
where 𝑣! and 𝑣! are the velocity in x-direction and y-direction, respectively.  
The element Reynolds number (local Re) was calculated as 
𝑅𝑒 =    !!
!
𝑉 !/!                                                  (Eq. 3) 
where 𝑢 is the mean velocity of the flow in an element, and V is the volume of the 





geometrically corresponding cylinder without the impeller to get a quick convergence at 
relative tolerance set as 0.001. 
3.2.3 Analysis for aggregates and metabolism 
 Samples of cell aggregates were analyzed for cell number, viability, and 
metabolic products. Briefly, 0.5 to 1.5 ml of samples were taken and placed still for 5 
min. Supernatants were filtered, stored in -20°C, and tested for glucose, lactate, and pH in 
a blood gas analyzer (Radiometer, ABL 710). Light microscopy images were captured 
using Axiovert phase contrast microscope (Zeiss). The total number of cell aggregates 
Nagg in a 1-ml sample was analyzed by using the “Embryoid body analysis” module in 
Celigo imaging cytometer (Brooks). The average equivalent diameter of aggregates d and 
the size of each aggregate in the sample were also measured in this analysis. For counting 
the cell number in a 1-ml sample Ncell and the cell viability, cell aggregates were 
dissociated by Accutase, stained with 0.4% Trypan Blue, and counted by Countess 
automated cell counter (Life technologies). The average cell number per aggregate N = 
Ncell/Nagg was calculated in 8 samples containing aggregates in different average 
diameters d from three independent culture cycles. In the plot of N-d, the data points fit 
best to a 3rd-order polynomial, defined by having the smallest R2 value comparing to 
other fitting functions. Dissolved oxygen (DO) level in the suspension medium was 
monitored real-time using a non-invasive optical fiber probe and PSt3 sensor spots via 





3.2.4 Immunofluorescent staining of cell aggregates in suspension culture 
Whole aggregate staining was performed for immunofluorescence microscopy as 
described before [116]. Fluorescent images of whole cell aggregates were captured and 
analyzed by LSM 510 META confocal microscope (Zeiss).	  
3.2.5 Karyotyping 
Karyotype of hiPSCs was examined by a certified cytogeneticist using G-banding 
(300-500 bands) method as previously described [11]. At least 20 metaphases were 
checked for each sample. For example, passage number of BC1 p30+21+21 means that 
the examined BC1 cells has been cultured for 30 passages on MEF, followed by 21 
passages on VNT-N and 21 passages in bioreactor. For TNC1 p30+17+19, there have 
been 30 passages on MEF, 17 passages on Matrigel, and 19 passages in bioreactor. 
3.2.6 In vitro spontaneous differentiation of germ cells 
Single cells were seeded in ultra-low-attachment plates in ESC medium 
supplemented with 10% fetal bovine serum (FBS, Hyclone) at 3.3×105 cells/ml to initiate 
EB formation. For iPSCs maintained in suspension in spinner flasks, cell aggregates were 
washed, and the entire medium was changed from E8 to differentiation medium to induce 
transformation from cell aggregates to EBs on day 3 after passaging. After 8 days, EBs 
were transferred onto gelatin-coated plates and attached. Differentiated cells on day 12 
were stained for fluorescence microscopy as described.  
3.2.7 Teratoma formation assay 
The use of immunocompromised mice for teratoma formation assay was approved 





performed as we described before [11]. Approximately 5×106 hiPSCs were collected after 
Accutase digestion of the culture in spinner flask for more than 10 passages, washed with 
PBS and resuspended in 200 ml diluted (1:1) Matrigel solution (BD). Cells were injected 
intra-muscularly into NOD/SCID/IL2RG(γc)-/- immunocompromised mice with a further 
reduced level of natural killer cells. Teratomas were excised 6-10 weeks after injection. 
After sectioning, slides containing various regions of teratomas were stained by H&E and 
analyzed under microscope. 
3.2.8 Cryopreservation and recovery of hiPSCs in suspension culture 
Cell aggregates on day 2 or day 3 were pre-treated with 10 µM Y27632 for 1 hour 
and dissociated into a single cell suspension with Accutase. After washing with PBS 
once, cells were suspended in E8 + 10 µM Y27632 and distributed into Cryovial aliquots. 
The same amount of E8 + Y27632 + 20% (in volume) DMSO cryopreservation medium 
was added dropwise. Cells were immediately frozen cells at -80°C in isopropanol 
freezing containers overnight, and transferred to liquid nitrogen for storage. For recovery 
from frozen stock, the cells were thawed by following standard cell culture protocol. 
Single cells were seeded at 5×104 cells/cm2 in either Matrigel- or VNT-N-coated 150-cm2 
flasks or ultra-low attachment plates, or at 5×105 cells/ml directly in spinner flasks at 








3.3.1 Adaptation and robust growth in feeder-free adhesion culture 
To prevent contamination of feeder cells in suspension culture, we first 
acclimated hiPSCs expanded in conventional MEF culture conditions [11] into feeder-
free condition. BC1 and TNC1 were transferred directly to E8 medium [73] on culture 
plates coated with diluted Matrigel or on purified recombinant	  vitronectin substrate [73]. 
We found that a step-by-step adaptation process, which is typically associated with other 
feeder-free conditions [165-167], is not required when we switched to E8 feeder-free 
conditions. Culture on either Matrigel or VNT-N supports robust and long-term culture of 
adherent, undifferentiated hiPSCs as a monolayer in adhesion (Figure 3-1). The hiPSCs 
were routinely passaged in single cells (using Accutase) or in small clumps (by EDTA) 
[73] at a split ratio of 1:8 to 1:12 every 3 to 4 days. They expressed TRA-1-60, SSEA4, 
OCT4, and NANOG, that are markers for undifferentiated hPSCs (Figure. 3-1, C-E). 
After more than 30 passages cultured in E8 medium and feeder-free conditions, hiPSCs 
maintained normal karyotype (Figure 3-1, F). These hiPSCs were able to form EBs in 
vitro containing cells from all three germ layers (Figure 3-2, A), confirming that the 
hiPSCs retained their pluripotency. We also examined directed hematopoietic 
differentiation of BC1 and TNC1 cultured under the E8 feeder-free conditions for at least 
10 passages. Using forced aggregation method in 96-well plates [168-170] in a feeder-
free and serum-free condition, we found that on day 14,  ~25%-80% of the differentiating 
hiPSCs were CD34+CD45+ HSPCs (Figure 3-2, B). Moreover, hiPSCs expanded in E8 





lineages as hiPSCs expanded in MEF culture conditions in the standard CFU assay [170, 
171] (Figure 3-2, C). 
 
 
Figure 3-1. Long-term adhesion culture of hiPSCs in feeder-free conditions in E8 
medium 
Morphology (A), expansion rate (B), and expression of pluripotency markers (C-E) of hiPSCs 
cultured on feeder or feeder-free substrates. (F) Karyotypes of hiPSCs after long-term culture on 
Matrigel or xeno-free VNT-N in E8. Passage numbers represent the passages in feeder-free 
conditions. Scale bars represent 200 µm, except for those in images of TNC1 in (E), which 












Figure 3-2. Spontaneous and directed hematopoietic differentiation of hiPSCs 
culture in E8 medium 
(A) Immunofluorescence staining for markers of germ cells (in red), including AFP (endoderm), 
CD31 (mesoderm), and β-3-tubulin (ectoderm). (B) Morphology and flow cytometry plots of the 
EBs and CD34+CD45+ HPCs derived from hiPSCs by FA-EB method after long-term expansion 
in E8 feeder-free conditions. (C) Representative images and colony counting of different types of 










3.3.2 Serial passaging and expansion in static suspension culture 
It has not been reported whether the significantly simplified E8 medium is 
sufficient to support the survival and proliferation of undifferentiated hPSCs in 
suspension culture. Thus our studies began by establishing a static suspension culture 
condition in E8 medium for serial passaging and expansion of hiPSCs. BC1 cells cultured 
on E8 feeder-free conditions (E8-Matrigel or E8-VNT-N) for at least 3 passages were 
seeded as a single cell suspension in E8 medium supplemented with Y27632 on the first 
day [123]. The cells survived and formed convex dish-shaped aggregates within 24 hours 
due to the gravity force (Figure 3-3, A). The size of the cell aggregates gradually 
increased corresponding to the cell number along the culture period. BC1 cells expanded 
in static suspension in E8 medium with an average rate of 3.7±0.9 fold per passage, 
3.7×106 fold increase in total with >99% of the cells being TRA-1-60+ after 13 passages 
(Figure 3-3, B-C). We also examined the differentiation potential of expanded cells, 
using the spin-EB method [168-170]. We found that under the hematopoiesis-inducing 
condition, leukocyte-like cells emerged around day 10 (Figure 3-3, D) with 46.8% ± 
1.6% of the cells becoming CD34+CD45+ HPCs (Figure 3-3, E). These results indicate 
that undifferentiated hiPSCs can be expanded in suspension in E8 medium supplemented 






Figure 3-3. Serial passaging of hiPSCs in static suspension in E8 medium 
(A) Light microscope image of aggregates after 48 hours post-inoculation of single suspension 
BC1 cells in ultra-low attachment plates. (B) BC1 cells cultured in E8 medium, expanded in static 
suspension culture for 13 passages (45 days, n = 3). (C) Flow cytometry plots (n = 3) of TRA-1-
60 expression in hiPSCs after 13 passages in static suspension.  (D) Light microscope image of 
HPC-like single suspending cells emerging around a spin-EB on day 14. (E) Flow cytometry 
plots (n = 2) of CD34 and CD45 expression in day-14 spin EBs. NC = negative control. Scale 
bars = 200 µm. 
 
3.3.3 Computational fluid dynamics (CFD) analysis of glass-ball spinner flask 
Many Previous studies suggest that an adaptation of hPSCs expanded in adherent 
culture to suspension culture in static conditions is needed prior to inoculation in dynamic 
suspension culture [112-114]. To support a robust production of hiPSCs from the bench 





culture to dynamic suspension culture in spinner flasks. A key parameter of spinner flasks 
to control is the agitation forces, which should be sufficient to ensure homogeneous 
distribution of cell aggregates, nutrients and oxygen, but not too severe to harm the cells. 
Human PSCs are sensitive to high shear stress that may cause unexpected cell death [114, 
122] and differentiation [126, 173]. Thus the velocity field profile and the shear stress 
distribution in the vessel are major considerations in the bioreactor design and setting for 
suspension culture of hPSCs. Spinner flasks equipped with pendulum-shaped (glass-ball) 
impellers were advantageous compared to other impeller types in previous studies [112, 
119] that might be due to mild shear stress generated by the smooth surface. Therefore, 
we chose the CELLSPIN system with a 100-ml spinner flask equipped with a single 
glass-ball stirring pendulum as the platform for hiPSC suspension culture. To predict the 
hydrodynamic property, we performed CFD analysis for a 3-D model of the glass-ball 
spinner flask. The physical properties of 37°C pure water were applied to approximate 
the properties of a single cell suspension in E8 medium during the first 12 hours after 
inoculation when the cells are most vulnerable to high shear stress. The simulation of the 
steady-state CFD at agitating speeds of 40 rpm, 60 rpm and 75 rpm (maximum spinning 
speed available of the system) was performed. A stable flow profile was found in all 
agitating speeds examined without inadequate mixing or large disturbing turbulence 
(representatively showing 60 rpm, Figure 3-4, A). Highest local Reynolds number, Re, 
was found at the small area tracking the rotating pendulum, which increased from laminar 
flow regime (Re < 1000) to laminar-turbulent transition regime (1000 < Re < 2000) [174, 
175] as the agitating speed increased (Figure 3-5, A). The profile of the z-direction 





the rotating pendulum provides appropriate convective flow in the vertical direction that 
enhances the mass transfer (Figure 3-4, B). At the maximum spinning speed, 75 rpm, the 
highest shear stress was determined as 0.152 N/m2 (1.52 dyn/cm2) at the point near the 
farthest reach of the glass ball from the spinning axis (Figure 3-4, C). This shear stress 
level is lower than spinner flasks equipped with other types of impellers, such as pitched-
blade impeller (2-5.2 dyn/cm2, 50-100 rpm) [176] and paddled impeller (4.5-7.8 dyn/cm2, 
80-120 rpm) [122, 177], indicating mild hydrodynamic impact on the cells. 
 
 
Figure 3-4. Initiation and optimization of dynamic suspension culture in E8 medium 
(A-C) 3-D CFD analysis of the velocity field at different agitating speeds in 100-ml glass-ball 
type spinner flasks. (A) Absolute value of velocity vectors of the fluid represented by heat map 
on two x-y slices at the agitating speed of 60 rpm. (B) Vertical flow in the bioreactor at 40 rpm. 
Heat plot on an x-z slice showed distribution of vertical flow. The sign of the value indicated 
directions of the vectors. Red solid lines were streamlines of the velocity field. (C) Heat map of 
shear stress distribution at the x-y slice. (D-G) Direct adaptation of BC1 cells in dynamic 
suspension culture from feeder-free adhesion culture at 40 rpm, 60 rpm, and 75 rpm. (D) 
Representative images of the cells aggregates on day 1, day 3, and day 5 after seeded as single 
cells at different agitating speeds. Scale bars = 200 µm. (E) Box-and-whisker plot of the sizes of 
cell aggregates. (F) Growth curves of a 5-day culture in the first passage in spinner flask at 40 
rpm, 60 rpm, and 75 rpm. Means ± SD, n = 3. *P < 0.05; **P < 0.01; ***P < 0.001. (G) Cell 














Figure 3-5. Additional information about optimization of dynamic suspension 
culture in spinner flask 
(A) Illustration of cell Reynolds number calculated in CFD analysis of 100-ml glass-ball spinner 
flask. Within the performed agitating speed, the distribution of the cell Reynolds number shows 
the same pattern at different speed, only with variant scale of values. (B) The coefficient of 
variation (SD/Average×100%) in average the samples of cell aggregates from different time 
points during a 5-day culture at 40 rpm, 60 rpm and 75 rpm. Two-way ANOVA, P = 0.0188, 
followed by Bonferroni posttests. **P < 0.01, ns = not significant. (C) Representative image of 






3.3.4 Optimization of agitating speed and cell split interval 
BC1 cells cultured in E8-Matrigel condition were used for the optimization of 
agitating speed and cell split interval. Consistent with previous studies [111, 112], 
preliminary experiments using seeding density lower than 4×105 cells/ml showed 
inconsistent cell survival and proliferation (data not shown). Thus, we used 4×105 to 
5×105 cells/ml as the seeding density for all following experiments. After treatment with 
ROCK inhibitor and dissociation, a single cell suspension of BC1 hiPSCs from feeder-
free adhesion culture was directly inoculated into the spinner flask with 45 ml of E8 + 
Y27632. Cell growth at agitating speeds of 40 rpm, 60 rpm, and 75 rpm were compared, 
and three independent repeats were performed in each condition (n = 3). Within 24 hours, 
hiPSCs formed spherical aggregates with diameters of 104.2 ± 44.8 µm, 80.6 ± 20.3 µm, 
and 60.8 ± 16.5 µm on average in 40 rpm, 60 rpm and 75 rpm, respectively (Figure 3-4, 
D-E). The cell aggregates gradually increased in size along the culture period reaching 
120-300 µm on Day 5. This is partially due to aggregate agglomeration, but mostly due to 
the expansion of the cells with 2-3 fold increase after 5-day culture (Figure 3-4 F-G). 
These results further demonstrated significantly higher cell density (Figure 3-4, F, P = 
0.0188) without compromising cell viability (Figure 3-4, G) in hiPSCs cultured in 
agitation rate of 60 rpm. Moreover, hiPSCs formed more homogeneous aggregates at 60 
rpm compared to hiPSCs cultured in 40 rpm and 75 rpm (Figure 3-4, E and Figure 3-5, 
A). The cell expansion rate decreased from day 3 to day 4 (Figure 3-4, F) while the cell 
viability varied on day 5 (Figure 3-4, G). Therefore, we decided to culture the cells at 60 





3.3.5 Characterization of hiPSCs in dynamic suspension culture 
We continued to characterize BC1 cells cultured in the spinner flasks for 
pluripotency associated marker expression, apoptosis level, and metabolism. We found 
that >98% of the cells are positive for TRA-1-60, SSEA4, NANOG, and OCT4 after 4 
days of culture by flow cytometry analysis (Figure 3-6, A). The fluorescent images by 
confocal microscopy showed the nuclear expression of OCT4 with membrane 
localization of SSEA4 in BC1 cell aggregates sampled from suspension culture on day 3 
(Figure 3-6, B), indicating the maintenance of the undifferentiated state inside the cell 
aggregates. We further found that the cell number per aggregate increased in the order of 
the cubic diameter -- the volume (Figure 3-6, C). Together with the confocal z-stack 
images of cell aggregates, our data suggested an even distribution of cells throughout the 
entire aggregate without compact center or hollow cavity. The rate of apoptosis in the cell 
aggregates was found to be 1.56% ± 0.1% (n = 3, Figure 3-6, D), indicating no severe 
programmed cell death due to the aggregate formation and the dynamic culture. Cell 
metabolism was monitored by measuring the consumption of glucose, the accumulation 
of lactate, the change of pH and the oxygen partial pressure (pO2) in the culture medium. 
We found that by replacing 2/3 of the medium daily with pre-warmed fresh E8, the 
consumption of glucose did not exceed 40%.  Also, the concentration of lactate was 
restricted under 10 mM (Figure 3-6, E), and the pH dropped to 6.75 by day 5 (Figure 3-6, 
F). For real-time monitoring of pO2 in the medium, a non-invasive O2 sensor and optical 
fiber probe were equipped to the bioreactor [178]. We show that the pO2 was kept above 
15% (Figure 3-6, G), indicating a sufficient oxygen supply merely by diffusion through 





with the exponential growth on the first three days followed by a reduced expansion rate 
after day 4 when the cell density reached ~1.5 × 106 cells/ml (Figure 3-4, F). 
 
Figure 3-6. Characterization of cell aggregates in spinner flasks 
(A-B) Expression of the markers for undifferentiated state in BC1 cultured in spinner flasks. (A) 
Flow cytometry plot (n = 3) of TRA-1-60+, SSEA4+, NANOG+, and OCT4+ cells on day 5. Gray 
area represents isotype control. (B) Confocal microscope images of the immunofluorescence 
staining for OCT4 (in green) and SSEA4 (in red) at the center z-slice of a cell aggregate on day 3. 
DAPI stained for nuclei. Scale bar = 100 µm. (C) A fitting curve of the cell number per aggregate 
to the diameter of the aggregate, means ± SEM, n = 300-2000. (D) Flow cytometry plots (n = 2) 
of TUNEL assay on day 3 aggregates, means ± SD, n = 3, NC = negative control, PC = positive 
control. (E-F) Concentration of glucose and lactate (E) and pH (F) in the media samples. Note: 
the two data points on the same day represent the concentration before and after media change, 
means ± SD, n = 3. (G) The pO2 level as percentage of the O2 saturation in three independent 











3.3.6 Serial passaging and expansion of hiPSCs in suspension culture 
To meet the requirement of scale-up processes for hiPSC production, serial 
passaging and extended expansion of BC1 and TNC1 cells cultured in our bioreactor 
system was tested. Human iPSCs were inoculated into spinner flasks as mentioned above, 
cultured for 3 to 4 days, passaged as a single cell suspension, and re-inoculated at the 
same conditions. Both BC1 and TNC1 cells were maintained in spinner flasks for at least 
2.5 months with 25 passages. During the culture period, BC1 showed an average 
expansion rate of 2.4±0.3 per passage, while TNC1 expanded 3.5±0.5 folds per passage 
on average (Figure 3-7, A), indicating variation of growth rate in suspension culture 
between the two different cell lines. The cells maintained high viability during the serial 
passaging in suspension. The overall viability was 92.9% ± 2.1% for BC1 and 95.0% ± 
1.6% for TNC1 (Figure 3-7, B). Both cell lines were also maintained in their 
undifferentiated state, as indicated by 95-100% positive stain of TRA-1-60, SSEA4, 
OCT4, and NANOG during the expansion period (Figure 3-7, C). Furthermore, BC1 and 
TNC1 cultured for up to 20 passages in spinner flask (plus at least 20 passages in feeder-
free adhesion culture before transfer to suspension culture) retained normal karyotypes 






Figure 3-7. Serial passaging and expansion of hiPSCs in xeno-free condition 
(A-B) The expansion fold (A) and the cell viability (B) at the end of each passage during the 
expansion of BC1 and TNC1. (C) The percentage of TRA-1-60+, SSEA4+, OCT4+, and NANOG+ 
cells in the aggregates at the beginning of the suspension culture (passage 0) and along the culture 
period (passage 6, 13, 19, and 25). (D) G-banding karyotyping of BC1 and TNC1 after extensive 
culture in spinner flask. The TNC1 cell line had been undergone 5 times of freeze-thaw cycles in 
suspension culture. 
 
3.3.7 Differentiation potential of hiPSCs in suspension culture 
BC1 and TNC1 hiPSCs cultured in spinner flasks for more than 10 passages were 
tested for their pluripotency by in vitro and in vivo differentiation methods. For in vitro 
assay, by simply replacing the entire E8 medium with differentiation medium of day-2 





started spontaneous differentiation under the stimulation of 10% serum (Figure 3-8). 
After 8 days in spinner flask followed by 4 days on gelatin-coated tissue culture plates in 
differentiation medium, cells of all three germ layers could be detected by 
immunofluorescent staining of specific markers (Figure 3-9, A). In contrast, 
undifferentiated hiPSCs on day-0 showed negative staining of all germ markers (data not 
shown). For in vivo assay, BC1 and TNC1 harvested from suspension culture in spinner 
flasks were injected into immunocompromised mice and were able to form teratomas 
containing cells of all germ layers, including glandular epithelium, chondrocytes, and 
neural rosettes (Figure 3-9, B). Directed hematopoietic differentiation potential was also 
tested as previously described (Figure 3-9, C). Differentiating BC1 and TNC1 cells 
contained 43.57% ± 4.35% (n = 3) and 43.22% ± 7.13% (n = 3) CD34+CD45+ HPCs on 
day 14 of differentiation, respectively. The CFU assay measuring hematopoietic 
progenitors showed that hiPSCs cultured in spinner flasks were able to generate colonies 
of different hematopoietic cell lineages. The total number of CFUs was comparable or 
significantly larger (P = 0.0307, n = 3) than cells cultured in parallel in adhesion cultures 






Figure 3-8. Transfermation from cell aggregates to EBs during the spontaneous 
differentiation of hiPSCs in the bioreactor 
E8 medium was replaced by differentiation medium containing serum on day 2. Cells started to 
differentiate and formed EB structures (arrows in images of Day 5 and Day 8). EBs were 







Figure 3-9. Differentiation potential of hiPSCs after prolonged expansion in 
bioreactor 
(A) Immunofluorescence analysis of in vitro spontaneous differentiation of day-3 hiPSC 
aggregates. Germ cell markers (red): alpha-fetoprotein (AFP, endoderm), CD31 (mesoderm), and 
β-3-tubulin (ectoderm). (B) H&E staining of biopsies of teratoma generated from hiPSCs in 
immunodeficient mice, n = 2 for each cell line. Black arrows indicate glandular epithelium. (D) 
Exemplary microscope images and flow cytometry results of CD34+CD45+ cells from directed in 
vitro hematopoietic differentiation. The percentage of CD34+CD45+ cells is presented as mean ± 
SD, n = 3. (D) CFU assay. (i) Representative images of different types of colonies in CFU assay. 
BFU-E: burst-forming unit-erythroid; CFU-E: erythroid; CFU-GEMM: granulocyte-erythroid-
macrophage-megakaryocyte, CFU-GM: macrophage-granulocyte. The hiPSCs cultured in spinner 
flasks (SF) were compared with the parallel feeder-free culture of the same cell line in adhesion 
(AD). The total number of CFU was analyzed by the two-tailed Student’s t-test, means ± SD, n = 











3.3.8 Cryopreservation and recovery of hiPSCs in suspension culture 
It has been reported that E8 medium with 10% DMSO can be used as 
cryopreservation medium for hPSCs frozen in small clumps [159]. However, whether E8-
based freezing medium can support single-cell cryopreservation has not been reported. 
As the inclusion of Y27632 in freezing medium was proven to enhance single cell 
survival at thaw [177], we examined cryopreservation of hiPSCs harvested from 
expansion in bioreactors in E8 medium supplemented with 10% (in volume) DMSO and 
10 µM Y27632. Following at least two weeks of storage in liquid nitrogen, we thawed 
the frozen cells in both adhesion and suspension culture conditions. The viability of the 
frozen cells upon thaw was measured as 89% ± 4% for BC1 (n = 3) and 93% ± 2% for 
TNC1 (n = 3). Moreover, both BC1 and TNC1 showed good attachment and typical 
morphology of undifferentiated hiPSCs on Matrigel or VNT-N (Figure 3-10, A). The 
cells reached 80% confluence after 3 to 4 days in culture and were passaged routinely 
hereafter, indicating a rapid recovery and good adaptation back in adhesion culture. 
Thawed cells were also able to survive and form aggregates in both static and dynamic 
suspension culture (Figure 3-10, A). Three protocols for recovery were tested for the 
purpose of further expansion in suspension. Cells were thawed in adhesion (AD), ultra-
low attachment plate (UL), or spinner flask (SF) for the first passage, and then transferred 
directly to spinner flasks on the next splitting (AD-SF, UL-SF, and SF, respectively, 
Figure 3-10, B). We note that the first passage after thawing in static or dynamic 
suspension culture conditions usually required longer culture period (5 to 6 days) to allow 
enough cell growth for splitting (Figure 3-10, B). Cells regained typical expansion rate at 





with positive staining of TRA-1-60, SSEA4, OCT4, and NANOG after 5 passages 
(Figure 3-10, C). Cells in AD-SF and UL-SF conditions showed 2-3 folds higher 
expansion rate in the first passage than hiPSCs that were directly thawed in spinner flasks 
(Figure 3-10, B). The spin-EB hematopoietic differentiation of hiPSCs recovered from 
UL-SF protocol demonstrated an efficient differentiation into hematopoietic progenitor 
cells (Figure 3-10, D). Furthermore, hiPSCs were tested for karyotype stability after 
sequential freeze-thaw cycles using single-cell cryopreservation. After more than 5 times 
of sequential freeze-thaw process after adapted to completely xeno-free conditions, 
including at least 4 times of cryopreservation following UL-SF protocol, both BC1 and 
TNC1 after ~70 passages maintained normal karyotype (Figure 3-10, E and Figure 3-7, 
D), indicating a reliable cryopreservation protocol for hiPSCs throughout their useful 
lifespan. This xeno-free cryopreservation and recovery protocol completed our bioreactor 






Figure 3-10. Cryopreservation and recovery of hiPSCs cultured in suspension 
(A) Morphology of hiPSCs on day 3 after thawing either on Matrigel or VNT-N coated plates for 
adhesion culture, or in ultra-low attachment plates (UL) or in spinner flasks (SF) for dynamic 
suspension culture, respectively, from single-cell cryopreservation in E8-based freezing medium. 
Scale bars: 200 µm. (B) The expansion of hiPSCs from cryopreservation following three 
protocols. AD-SF or UL-SF: thawing cells in adhesion or in UL, respectively, and transferred in 
SF at first splitting. SF: directly thawing cells in spinner flask. The significance of difference 
between UL-SF and SF on the first passage after thawing was analyzed by two-tailed Student’s t-
test, means ± SD, n = 3. (C) Expression of TRA-1-60, SSEA4, OCT4, and NANOG at the end of 
passage 5 following a freeze-thaw cycle as determined by flow cytometry. (D) hiPSCs recovered 
from UL-SF protocol at passage 5 after thaw kept the potential to differentiate into CD34+CD45+ 
HPCs. (E) G-banding karyotyping of BC1 cells after total 72 passages with 30 passages on MEF, 









Following the demonstration that a ROCK inhibitor such as Y27632 permits the 
survival of single-cell hESCs [123], several groups utilized it to establish suspension 





124, 125, 164] as discussed in Chapter 1. Most of these approaches were based on serum-
free media that contains BSA Faction V or human serum albumin as the major protein 
component. The batch-to-batch variance of this animal-source product led to 
compromised defined medium [73]. Towards this, we first transferred hPSCs into the 
newly developed E8 medium on human vitronectin substrate, to avoid BSA and have a 
completely xeno-free condition with low concentration of protein components. We then 
demonstrated that E8 medium (with Y27632 on the first day of seeding) is sufficient to 
support hiPSC aggregation and survival, and serial passaging in the undifferentiated state 
using static suspension culture. 
We next aimed to optimize the protocol for dynamic suspension culture in spinner 
flasks. While there are many experimental and computational studies for assessing the 
flow dynamics in spinner flasks equipped with various types of paddle-shaped impellers 
[179-183], the relevant analysis for glass-ball spinner flasks has not been reported. We 
simulated the velocity field and shear stress of the flow in the glass-ball type spinner 
flask, providing reasonable prediction of the effect of flow on single cells during the first 
several hours after inoculation. Some rational approximations were applied to simplify 
the model, such as using the properties of 37°C water instead of the unknown data of the 
medium, omitting gravity due to its negligible effects on single cells compared to the 
agitating force, and ignoring the cell aggregation due to the complexity it would bring to 
the model. Although the model could not estimate the shear stress on the surface of cell 
aggregates after emergence, the method provides an efficient tool for the design and 
analysis of the bioreactors with complex vessel structures or non-standardized impeller 





(i.e. 40 rpm, 60 rpm and 75 rpm). Although small turbulent flow may occur at high 
agitating speeds according to the calculation of the local Reynolds number, the shear 
stress generated by the glass-ball impeller is considerably lower than by other types of 
impellers. Experimentally, we further found that an agitation speed of 60 rpm supports 
the formation of homogeneous cell aggregates, showing significantly higher expansion 
rates and relatively better cell viability than the other agitation speeds. As a comparison, 
hiPSCs formed relatively large aggregates on day 1 at 40 rpm, which reduced the 
potential of further proliferation due to the diffusion limitation. Moreover, occasions of 
undesired aggregate agglomeration, resulting in aggregates larger than 800 µm, were 
observed on later days due to insufficient agitating force. At 75 rpm, cell viability 
dropped significantly on day 1, leading to slower recovery and expansion. Based on these 
results, the optimal split interval at 60 rpm was next determined. We noticed a reduction 
in cell expansion after day 3 or day 4, which might be due to the diffusion limitation as 
cell aggregates grow. It is widely accepted that the diffusion limitation of oxygen in 
human tissue is 100 to 200 µm [184]. Therefore, we determined to split the cells on day 3 
or day 4 when most of the cell aggregate diameters reached ~150-200 µm. The 
concentration of glucose and lactate in the culture media also suggested a reduced growth 
after day 3, when the pH of the media drop to ~6.75 as cell density increased, which 
might be harmful for the hiPSC lines that are more sensitive to changes in pH and 
influence the expansion. This issue may be solved by gradually increasing the culture 
volume or the media change frequency. The inclusion of a non-invasive O2 probe-patch 





rotation of the impeller in the glass-ball bioreactor, which are normally difficult to equip 
with a standard large O2 probe [112, 120].  
Using the optimized operating conditions we demonstrate serial passaging and 
expansion of two integration-free hiPSC lines in completely defined xeno-free media in 
100-ml bioreactors. The cells exhibited homogeneous aggregate formation, steady 
expansion in their pluripotent state, and normal karyotype after ~20 passages. Note that 
one experiment of extended expansion of TNC1 cells in spinner flask (p30+6+21) 
showed abnormal karyotype (47, XXY). However, there is no evidence that it should be 
attributed to the suspension culture. In general, recently improved iPSC culture 
conditions reduce selective pressure for the growth of mutated cells that acquire growth 
advantages.  Although karyotypically abnormal cells were found occasionally after long-
term cultures under both adherent and suspension conditions, the frequency is low (5% of 
tested batches of hiPSCs and hESCs). The standard karyotyping or other genotyping 
methods like what we performed here will remain necessary to manage this inherent issue 
of long-term cell cultures. 
Undifferentiated hiPSCs expanded in bioreactors retained their potential of 
spontaneous and directed hematopoietic differentiation comparable to cells cultured via 
adherent culture. The transformation from day-2 or day-3 cell aggregates to EBs for 
spontaneous differentiation in the spinner flask demonstrate the possibility to use this 
system for a continuous bioprocess that begins with a large-scale expansion and directed 
differentiation in one single batch. Interestingly, although comparable amount of HPCs 
and CFU were derived from hiPSCs expanded in bioreactor as in adhesion, HPCs derived 





lineage rather than in myelocyte lineage. Further studies are needed to reveal the 
significance and the mechanism underlying the contribution of hydrodynamic forces to 
hPSCs differentiation in suspension. Studies of hematopoietic differentiation in spinner 
flasks are ongoing. 
The development of a single-cell cryopreservation protocol concluded the 
establishment of our chemically defined xeno-free suspension culture system. For 
continuous expansion, UL-SF protocol was the preferred method for recovery with small 
number of hiPSCs from cryopreservation. The hiPSCs can be directly thawed in a spinner 
flask; cells cultured in a spinner flask can be transferred back to VNT-N-coated surface 
for the applications that require adhesion culture, indicating good flexibility of the 
system. The single-cell cryopreservation protocol and the suspension culture system can 
significantly reduce the workload when handling cells in the scale required for 
translational uses. Furthermore, this xeno-free protocol of cryopreservation and recovery 
was theoretically proved to be compliant to a scale-up strategy for hiPSCs in suspension 
and under cGMP condition, allowing a yield of ~1×109 cells within 20 days after thawing 
of 1×106 frozen cells (Figure 3-11). The scale-up strategy, which includes multiple xeno-
free processes, employs 100-ml and 1-L spinner flasks, enabling the transition from lab 
scale to pilot scale of hiPSC expansion. The CFD simulation of the 1-L spinner flask 
(Figure 3-12) equipped with two glass-ball stirring pendulums (such as one from Integra 
Bio-sciences) indicated that it could be scalable using 1-L spinner flasks toward clinically 
relevant quantities of hiPSCs from a single batch . The simulation revealed a steady flow 
at the highest agitating speed of 75 rpm and an even lower maximum shear stress (0.047 





between the farthest points of the pendulums and the spin axis (r = 38.9 mm in Figure 3-
12, equivalent to impeller radius of paddle impellers) in the 1-L spinner flask is not much 
longer than the 100-ml spinner flask (r = 28.2 mm); thus, the highest velocity in 1-L 
spinner flasks is not much higher than that in 100-ml spinner flasks (vmax,1L = 0.309 m/s 
vs. vmax,100ml = 0.224 m/s). On the other hand, there is much more space between the 
pendulums to the flask wall in the radial direction (l in Figure 3-12, l 1L = 29.1 mm vs. l 
100ml = 3.5 mm). This causes a more moderate drop of velocity from the maximum at the 
far reach of the pendulums to zero at the flask wall in 1-L spinner flask compared to the 
100-ml spinner flask, leading to a significant decrease of the gradient of velocity, dvz / dx, 
which contributes to the majority of the shear stress. Before reaching steady state, 
stepping acceleration could be used to protect the cells from sudden exposure to high-
speed flow. Also, the liquid level of 600-ml medium in the 1-L spinner flask is similar to 
that of 60-ml medium in the 100-ml spinner flask, which was proven in this study not to 
cause any reduced O2 transport. While optimization of the agitation speed should be 
performed for different hiPSC lines to support appropriate size aggregate formation (for 
example, diameter of 50-80 µm after 24 hours), this direct scale-up process in 1-L 






Figure 3-11. Schematic presentation of the cryopreservation and scale-up expansion 
of hiPSCs in xeno-free culture system 
The days and the yield of hiPSCs are presented as approximate amount. Drawing not to scale. 
 
 
Another practical advantage of the system is relatively low cost. The high price of 
current commercially available serum-free media such as StemPro and mTeSR always 
hinders the universal application of the scale-up technologies for hiPSC expansion, 
especially for xeno-free media when albumin is required in the medium [73]. The 
simplicity of the medium dramatically cuts down the price (~30%-60%) and makes it 






Figure 3-12. CFD simulation of ~600 ml of culture media at steady state at 40 or 75 
rpm in a 1-L spinner flask 
(A) The velocity field on two representative cross-sections in the spinner flask at 75 rpm. (B) The 
cross-section of shear stress profile on the plane that showed the highest shear stress, which 
located around the far reach of the pendulums (red area). r is the distance between the far reach 
point of the pendulum and the spinning axis. l is the distance between far reach point of the 








In this chapter, we established a reproducible approach for rapid, economic, and 
scalable expansion of hiPSCs in xeno-free condition to meet the demand of practical 
research and clinical applications. The complete elimination of components from animal 
sources and remarkably reduced cost of this system provide a reliable technology for 
scale-up of hiPSC expansion and take a significant step toward the realization of stem 








4 Efficient and reproducible production of 
HSPCs and enucleated erythrocytes from hiPSCs 
 
Ex vivo generation of erythrocytes from hiPSCs would provide a renewable cell 
source of RBCs for treating transfusion-dependent patients, as well as a better 
understanding of human erythropoiesis. The key requirements in this approach include 
developing a robust and consistent method for the production of functional progenitor 
and progeny cells such as HSPCs from hiPSCs, and minimizing risk and variation due to 
the animal-derived products in cell cultures. In this chpater, we first developed an 
efficient system to generate HSPCs from hiPSCs under a feeder-free and xeno-free 
condition, in which all the animal-derived products were eliminated. Several crucial 
reagents were evaluated and replaced with FDA-approved pharmacological reagents, 
including Romiplostium (Nplate®, a thrombopoietin analog), and Plasbumin (human 
albumin). Human iPSCs generated from sickle cell disease (SCD) patients have a 
missense homozygous point mutation in the HBB gene encoding adult β-globin proteins 
and can be used as a model system to improve strategies of human gene therapy. 
Erythrocytes from either the HBB gene-corrected or its parental (uncorrected) iPSC lines 
derived from SCD patients were generated with similar efficiencies. Approximately 
~6%-10% of these erythrocytes indeed lacked nuclei, characteristic of mature 





HBB allele in the erythrocytes differentiated from genome-edited iPSCs.  Our results 
represent a significant step towards the clinical applications of genome editing using 
patient-derived iPSCs to generate disease-free cells for cell and gene therapies. 
4.1 Introduction 
Human iPSC is a promising cell source that can be easily derived from donor 
somatic cells and expanded indefinitely [9]. They would provide a potentially unlimited 
source of RBCs perfectly matching to patients or a favorable donor with any antigen 
types, especially the universal donor type and rare-phenotype matching RBCs [150, 185-
187]. Recently, hiPSCs derived from healthy donors or patients with blood-related 
disorders were successfully differentiated towards erythroid lineages and completed 
terminal maturation, which is marked by enucleation, blood antigen display, fetal-to-adult 
hemoglobin switch, functional oxygen carrying ability and many other characteristic 
features comparable with primary blood cells or those derived from primary HSPCs [188-
192]. 
The current methodology for the in vitro generation of RBCs from hiPSCs 
generally includes three distinguishable steps: (1) formation of definitive HSPCs that 
express both CD34 and CD45 markers (CD34+CD45+); (2) erythroblast specification and 
expansion; and (3) erythrocyte maturation. To complete step (1), various protocols were 
established to promote mesodermal commitment and hematopoietic specification of 
hiPSCs [193]. For example, co-culturing with mouse stromal cells [148, 188, 194] or 
human stromal cells [146, 195, 196] harbored hiPSCs or HSPCs in stromal niches that 





together with the latter two steps. Efficient feeder-free differentiation of hiPSC in 
monolayer adhesion culture on supporting substrates has not been established until a 
recent study showed that tenascin C could replace confluent OP-9 mouse stromal cell 
line, although the erythrocyte production from the new culture system has not been 
demonstrated [197]. The most commonly used method for step (1) so far is by forming 
EBs that are self-organized to mimic early human embryonic structures and development 
[198]. The mesodermal commitment and hematopoietic differentiation with EBs are 
further enhanced by adding exogenous cytokines such as BMP4, bFGF, SCF, VEGF, IL-
3, etc. [153, 191, 199-202]. There are a number of approaches to form EBs, such as 
hanging drop, self-aggregation in static/dynamic suspension and FA method. Among 
these approaches, others and we found that FA in 96-well plates and micro-patterned 
plates that forms individual EBs while preventing multiple EBs from fusion and 
agglomeration, efficiently generate CD34+CD45+ definitive HSPCs [13, 169, 189, 203-
205]. However, these studies used animal-derived products such as BSA [169, 206]. 
These xenogeneic and undefined reagents often cause low reproducibility and conflict 
with the strict requirements of clinical or pre-clinical applications [207, 208]. To search 
for a robust and efficient culture condition to generate HSPCs, we seek to develop a 
serum-free and feeder-free system of hiPSC differentiation with a high level of 
reproducibility. Moreover, we also evaluated some FDA-approved pharmacological 
agents to replace TPO and BSA in culture medium, which is important for future clinical 
applications.  
Importantly, previous studies did not show the production of the corrected HBB 





lack of evidence in producing HBB protein after iPSC gene correction and differentiation 
could be due to: 1) defects in the donor vector that is unable to express the corrected gene 
from the endogenous regulatory element after genome targeting; 2) defects in the iPSC 
lines in these earlier studies that were derived from adult fibroblasts by vectors inserting 
and disputing the native human genome; 3) lack of an efficient differentiation method to 
generate mature erythrocytes that produce the adult form of beta-globin encoded by the 
HBB gene; or 4) combinations of the above.  
Using a specific guide RNA and Cas9 in CRISPR/Cas9 gene correction, we readily 
corrected one allele of the SCD HBB gene in human iPSCs by homologous 
recombination with a donor DNA containing the wild-type HBB and a selection cassette 
for targeted insertion. An ultimate task would be to efficiently and specifically target the 
SCD mutation in high quality hiPSCs (such as those free of vector insertion), differentiate 
them into erythrocytes expressing a high-level of HBB mRNA, and demonstrate the 
production of HBB-encoded protein from the corrected allele. In this chapter, we 
demonstrated that we achieved these objectives, and established an efficient and 
reproducible method that is applicable to generate enucleated and β-globin expressing 
erythrocytes from hiPSCs.  
4.2 Materials and Methods 
4.2.1 HSPC generation from hiPSCs using forced aggregation (FA) method 
The forced aggregation or “spin-embryoid body” (spin-EB) method in feeder- and 
serum-free conditions was modified from previously described protocols [13, 210, 211]. 






Table 4-1. Formulation of SFM for HSPC differentiation 
Components Final concentration Resources 
Iscove’s modified Dulbecco 
medium (IMDM) ~ 50% Gibco 
Ham’s F-12 ~ 50% Gibco 




(human albumin) Amgen 
Chemically defined lipid 
concentrate 1% Gibco 
GlutaMAX 2 mM Gibco 
L-ascorbic acid phosphate 
magnesium salt 50 mg/ml Sigma 
1-thioglycerol 437 mM Sigma 
Insulin-Transferrin-
Selenium-X 1x Gibco 
 
In brief, the SFM contain components including ITS and BSA. We also 
substituted BSA in the original SFM with FDA-approved human albumin made from 
pooled human venous plasma. One source is Plasbumin made by Grifols (NDC13533-





Systems), and 10 ng/ml BMP4 (R&D Systems). Cells (3, 000) were seeded into non-
treated round-bottom 96-well plates (Costar) in 50 µl per well, and centrifuged at 300×g 
for 5 min. From day 2 to day 14, the cells were cultured in SFM containing FGF2 (10 
ng/ml), BMP4 (10 ng/ml), SCF (50 ng/ml, R&D Systems), and VEGF-A (10 ng/ml, 
PeproTech). TPO (20 ng/ml, PeproTech) or romiplostim (Nplate, 20 ng/ml, Amgen) was 
added into the medium at day 11. Nplate is an US Food and Drug Administration (FDA) 
approved TPO analog [212].  On day 13-14, the suspended cells were harvested, and then 
filtered through 40-µm cell strainers (BD Biosciences) to remove EBs.  
4.2.2 Hematopoietic and erythroblast differentiation of hiPSC-derived HSPCs 
Hematopoietic and erythroblast differentiation of BC1, TNC1 and targeted iPSCs 
were done as described previously [205, 213]. Briefly, 5×105 cells/ml of either pooled or 
CD34+ enriched suspension cells after EB day 13-14 were cultured in SFM containing 
human albumin, SCF (100 ng/ml, R&D Systems), erythropoietin (EPO, 3 U/ml, R&D 
Systems), human holo-transferrin (100 µg/ml, R&D systems) and interleukin 3 (IL-3, 10 
ng/ml, R&D Systems). Cells were cultured at 37°C in a humid atmosphere of 5% CO2 in 
air for 10 days and the medium was changed once every three days. 
4.2.3 Erythroid terminal maturation of erythroblasts generated from hiPSCs  
We counted the erythroblast cell number at day 10 of erythroblast differentiation 
and expansion culture and washed erythroblasts twice with PBS after we confirmed the 
normal erythroblast phenotype by flow cytometry. We then seeded erythroblasts in 
erythroid terminal maturation medium (TM) at 1 million per ml at 37°C in a humid 





(Invitrogen) plus 3 U/ml Epo (R&D Systems), 500 µg/ml human holo-transferrin (R&D 
systems), 4 U/ml heparin (Sigma), 10 µg/ml insulin (Sigma), and 10% pooled normal 
adult human peripheral blood plasma (innovative-research, Cat# IPLA-N). Fresh medium 
with cytokines was added every 2 to 3 days. The cell density is maintained below 4 
million per ml. The maturating cells were taken for analysis at different days up to ten 
days from the beginning of terminal maturation. 
4.2.4 RNA extraction and quantitative RT-PCR to measure gene expression 
RT-PCR analysis of globin gene expression was done as described before [214]. 
All experiments were performed in triplicate and a non-template control (lacking cDNA 
template) was included in each assay. Relative gene expression was normalized to the 
housekeeping gene GAPDH. 
4.2.5 Western blot of HBB protein production 
Western blot for analyzing HBB protein level in differentiated cells is carried out 
using a monoclonal antibody against human HBB (Santa Cruz Biotechnology, sc-21757) 
and GAPDH (Cell Signaling Technology, Cat. 5174), according to the manufacturer’s 
instructions. We used the protein extract from the same number of cells at different stages 
of differentiation to estimate HBB content in differentiated cells.  
4.2.6 O2 binding capacity and affinity 
O2 equilibrium curves of day 8 erythrocytes after terminal maturation (TM8) 
differentiated from iPSCs or fresh human CB as a control were determined using a 
Hemox-Analyzer (TCS Scientific, New Hope, PA) in accordance to manufacturer’s 





4.3 Results  
4.3.1 A complete xeno-free condition supplemented with human albumin for 
reproducible HSPC generation 
In our original medium formulation for hematopoietic differentiation, which was 
adapted from BPEL medium reported first by Ng et al. [210], BSA is a critical 
component in a serum-free medium to nourish the cells and induce efficient 
differentiation (Table 4-1). However, commercial sources of BSA, which are known as 
Cohn fraction V and enriched in bovine albumin proteins, also contain other proteins and 
bioactive substances including undefined amounts of fatty acids, hormones, and metal 
ions. We have tested several BSA preparations from different sources and selected one 
product that gave the best results regarding CD45+CD34+ HSPC production. However, 
different lots of BSA product gave inconsistent result even with the same hiPSC line such 
as BC1 (Figure 4-1, A). “Good” lots (such as BSA Lot #1 and #5 in Figure 4-1, B) could 
lead to efficient differentiation (Figure 4-1,A, left panel), while a “bad” lot (such as BSA 
Lot #2 to #4 in Figure 4-1, B) caused low viability on day 2, which led to the failure of 
EB formation, or large cystic EBs with no release of single HPCs (Figure 4-1, A, right 
panel). As a result, we had difficulties in establishing a standard culture condition for the 
differentiation of multiple hiPSC lines. To achieve consistent hiPSC differentiation to 
HSPCs, we replaced BSA in serum-free medium with Plasbumin, which is a clinic-grade 
agent enriched for human albumin made from serum plasma. We found that Plasbumin 
from several lots consistently gave significantly higher efficiency and smaller variation 





plate), compared to BSA fraction preparation (0.44±0.54×106 cells per plate) (Figure 4-1, 
B, mean ± SD, n = 15). 
 
 
Figure 4-1. Replacing BSA with human albumin in SFM increased the efficiency 
and consistency of HSPC differentiation 
(A) Representative images of day 2 and day 14 EBs from failed (left panel) and succeeded 
differentiations (right panel) using various lots of BSA and Human albumin (HuA) preparation in 
SFM. All scale bars represent 100 mm. (B) CD34+CD45+ HPCs generated from one 96-well plate 
of BC1 using SFM contained either BSA product or Human albumin of 5 different lot numbers 
each. Solid dots represent BSA group, and hollow dots represent Human albumin group. Mean ± 
SD, n = 15, p < 0.0001. 
 
4.3.2 In vitro Microvascular Networks from Varies Cell Sources 
We found that the addition of 20 ng/ml Romiplostium (TPO analog 
commercialized as Nplate) during the last stage of EB-mediated differentiation increased 





2), and also enhanced subsequent megakaryocytic differentiation as a replacement of 
TPO [204]. Therefore, we included the Nplate treatment (one dose added at day 11) into 
the differentiation medium to increase HSPC yield. 
 
 
Figure 4-2. Enhancing the yield of hematopoietic progenitors on EB day 13 and 
erythroblasts on ED day 10 by adding Nplate during FA-EB day 11 to day 13 
(A) Yield of CD34+, CD45+ and CD34+CD45+ per 96-well plate on FA-EB day 13. Nplate were 
added at the concentration of 20 ng/ml from day 11 to day 13 (n = 3, mean ± SD). (B) Fold 
increase of the yield of CD36+CD235a+ erythroblasts on ED day 10 between FA-EB cells with or 
without 3-day treatment of Nplate (n = 3, mean ± SD). 
 
4.3.3 Generation of enucleated erythrocytes from hiPSCs derived from blood 
We also proved that Plasbumin can be used to fully replace BSA in support of 
erythroblast differentiation under a serum-free culture condition, using either 
recombinant human proteins or human-sourced proteins. Recently we developed a 
method to generate human iPSC lines that are free of vector insertion in the genome from 





example, we used peripheral blood mononuclear cells (MNCs) from an adult SCD patient 
and established a proliferative erythroblast culture that was reprogrammed to iPSCs by 
one to two plasmids [11].  One of such established iPSC lines, TNC1, contains the 
homozygous SCD mutation (nt. 69A>T) in the HBB gene [14].  After extensive 
expansion under a feeder-free culture condition such as one with the E8 culture medium 
on vitronectin as substrates, the TNC1 and BC1 iPSCs maintain pluripotency and are 
karyotypically stable [213].  We also analyzed the hematopoietic and erythrocytic 
differentiation potential of blood-derived iPSCs by first generating definitive 
CD34+CD45+ HSPCs followed by erythrocyte production ex vivo.  In the first step, we 
used an improved method of forming individual EBs followed by hematopoietic 
differentiation that lasts 14 days (Figure 4-3, A), under a feeder-free and serum-free 
condition previously described [213].  Many hematopoietic cells released from EBs to 
culture medium by day 11-14 (Figure 4-3, B).  We found that 55-65% of the cells 
harvested from culture suspension co-expressed CD45 and CD34, characteristic 
phenotypes of definitive HPCs (Figure 4-3, C).  Compared to the input number of iPSCs, 
this was >3-fold expansion (Figure 4-3, D). 
Next, the harvested cells from culture suspension at day 14 after EB formation or 
the purified CD45+CD34+ cells were expanded in erythroid differentiation (ED) culture in 
the presence of SCF, EPO, IL-3 and holo-transferrin (Step II in Figure 4-3, A).  After 10 
days, the total cells expanded ~40-fold (Figure 4-3, E), turned reddish gradually (Figure 
4-3, F), expressed erythroblast markers such as CD36 and CD235a (Glycophorin A) and 
CD45 (not shown) at day 9-10 (Figure 4-3, G), and displayed erythroblast morphology 





Figure 4-3. A feeder- and xeno-free culture condition for the hematopoietic 
differentiation of hiPSCs 
(A) A three-step differentiation strategy from iPSCs to hemoglobinized and enucleated 
erythrocytes, including forced aggregation mediated hematopoietic differentiation (EB), erythroid 
differentiation (ED), and erythroid terminal maturation (TM). (B-D) Characterization of EB day 
14 cells of TNC1 iPSC cultures. (B) Phase-contrast image of an EB and surrounding 
hematopoietic cells. Scale bar: 200 µm. (C) Representative flow cytometric analysis of 
suspension cells harvested EB14 cells that co-express CD34 and CD45. The gates in all flow 
plots were set based on corresponding fluorescent isotype controls. (D) The yield of CD34+, 
CD45+, and CD34+CD45+ cells derived from one input hiPSC. Means ± SD, n = 4. (E-H) 
Erythroid differentiation (ED) step resulting in erythroid commitment, and erythroblast formation 
and expansion. (E) The accumulated expansion of cell numbers during the ED step. Means ± SD, 
n = 3. (F) Gradual color changes of cell pellets along the ED step. (G) A epresentative flow 
cytometric plot indicates that the majority of the ED10 cells express immature erythrocytes 









The erythroblast-like cells were allowed to terminally differentiate in culture with 
EPO, heparin, insulin and a high concentration of holo-transferrin (Step III in Figure 4-3, 
A).  We also found that adding human plasma, which enhanced erythrocyte enucleation 
of erythroblasts derived from primary CD34+ cells [216], also stimulated terminal 
differentiation of human iPSC-derived erythroblasts as reported recently [190, 192].  
Upon terminal differentiation, the cells expanded for another 10-fold (>3 cell divisions) 
after 7-8 days before ceasing cell proliferation. The differentiated cells at this stage 
turned reddish, lost CD45 expression in the majority of cells (>98%), continued CD235a 





and enucleated (~10.6%) cells (Figure 4-4, A-D).  In addition to Band3+ and CD235a+ 
erythrocytes (>98%), we consistently observed a small population (0.2% to 1.6%) of 
nucleated cells in the harvested suspension cells after 6-8 days after terminal 
differentiation that express CD45, but lack CD235a and Band 3 expression (Figure 4-4, 
C).  Morphological staining suggests that these CD45+ cells resemble monocytes or 
macrophages (data not shown).  Using quantitative RT-PCR analysis, we observed that 
the HBB gene expression in erythroblasts (ED10) and erythrocytes (TM8) from either 
TNC1 iPSCs or CB CD34+ cells under the same improved culture condition, while the 
HBG gene expression is ~10–fold than HBB (Figure, 4-4, F).  We further confirmed that 
enucleated cells expressed hemoglobin as stained by benzidine (Figure 4-4, G).  Similar 
data were obtained using the BC1 iPSC line (Figure 4-5 and 4-6), with an enucleation 
rate of 4.7% ±2.8% and erythrocytes producing HBB as well as HBG proteins.  Thus, we 
demonstrated that we can generate a population of human mature erythrocytes from 






Figure 4-4. Terminal maturation of TNC1 iPSC-derived erythroblasts 
(A) Cell expansion during the TM step. Means ± SD, n = 3. (B) Suspension of 90 million TM day 
8 (TM8) cells in 1 ml PBS. (C, D) Representative flow cytometric plots of TM8 cells, with >98% 
cells co-express CD235a and Band3, and ~10% enucleation marked by negative staining of 
DRAQ5. (E) Phase-contrast and fluorescent images of TM8 cells. Blue arrows indicate 
enucleated erythrocytes. Scale bars: 30 µm. (F) Quantitative PCR analysis of gene expression of 
HBB (adult) and HBG (fetal) at different differentiation stages of TNC1 cells, comparing to the 
cultures of CB CD34+ cells. Means ± SD, n = 3. (G) benzidine (brown color) for hemoglobin and 
Wright-Giemsa (nuclear DNA) staining of TM8 cells. 40× image. Scale bar: 50 µm. Blue arrows 






Figure 4-5. Hematopoietic differentiation and erythroid differentiation of BC1 
iPSCs 
The BC1 iPSCs, derived from a health adult bone marrow CD34+ cells, were differentiated to 
erythrocytes as described in Figure 4-3 (for TNC1 iPSCs).   (A) The yield of CD34+, CD45+, and 
CD34+CD45+ cells derived from one input iPSC, after EB formation and hematopoietic 
differentiation at day 14 (EB14). Means ± SD, n = 4. (B, D, F) Representative flow cytometry 
analysis of BC1 cells on EB14, erythroid differentiation at day 10 (ED10), and terminal 
differentiation day 8 (TM8), respectively, as described in Figure 4-3. (C, E) Cell expansion 






Figure 4-6. Terminal maturation of BC1 iPSC-derived erythroblasts 
(A) Benzidine (gold brown color) and Wright-Giemsa staining of TM cells. (B) Wright-Giemsa 
staining of TM cells. 40× images. Scale bar: 50 mm. (C) Representative flow cytometry analysis 
of fetal (HbF) and adult (HbA) hemoglobin in TM8 BC1 cells. (D) Quantitative PCR analysis of 
gene expression of HBB (adult) and HBG (fetal) at different differentiation stages of BC1 cells, 
comparing to CB CD34+ cells. Means ± SD, n = 3. 
 
 
4.3.4 Production of corrected HBB proteins in erythrocytes derived from genome-
edited SCD iPSCs 
We specifically measured the level of corrected HBB gene expression and protein 
in ex vivo generated erythrocytes (TM8) from the gene-edited SC15-Cre2 clones, in 





PCR primers and the HBB antibody would not distinguish the wild-type and βs forms, 
allowing us to quantitatively compare the level of HBB mRNAs or proteins in 
erythrocytes from the corrected SC15-Cre2 or parental TNC1 iPSCs.  By RT-PCR, the 
level of HBB mRNA in SC15-Cre2 after terminal differentiation (TM8) increased further 
over those at earlier stages, but appeared >10-fold lower than those in erythrocytes from 
CB or TNC1 iPSCs (Figure 4-7, A).  By Western blot, the HBB protein level in the 
erythrocyte culture from the SC15-Cre2 iPSCs is comparable to that from the parental 
TNC1 iPSCs (Figure 4-7, B).  The HBB protein level in SC15-Cre2 derived erythrocytes 
appeared to be higher than that from the SC15 iPSCs, the genome-edited clones without 
the removal of the PGK-puromycin selection cassette located in the HBB intron 1. 
We measured the HBB and HBG proteins in the native form of hemoglobin 
tetramers in individual cells by flow cytometric analysis (Figure 4-7, C).  We detected 
>85% and >98% of cells expressed HBB and HBG proteins, respectively.  The level of 
HBB proteins appears ~10-fold lower that that of HBG (Figure 4-7, C).   
We also measured the functionality of O2 binding by hemoglobin produced in the 
erythrocyte generated from hiPSCs, in comparison with primary CB erythrocytes (Figue 
4-7, D).  The iPSC-generated cells have an O2-binding curve similar to that of cord blood, 
except that the affinity is slightly higher (p50 is 16.6 in SC15-Cre2 vs. 22.9 for CB). This 
may reflect the fact that HbF (containing HBG), which has a higher affinity for oxygen, 






Figure 4-7. Analysis of globin gene and protein expressions of the corrected 
erythrocytes and their function 
(A) Quantitative RT-PCR analysis of HBB and HBG gene expression in iPSCs, after 
hematopoietic differentiation (EB14), erythroid differentiation (ED10) and terminal maturation 
(TM8) from SC15-Cre2 and parental TNC1 iPSCs and a control of cord blood (CB) CD34+ cells. 
(B) Western blot analysis of adult hemoglobin beta (HBB) protein level during the differentiation 
of hiPSC clones before and after correction and excision. The relative levels of full-length HBB 
proteins normalized to the GAPDH control are also indicated. (C) FACS analysis of intracellular 
adult and fetal hemoglobin protein expression of maturated erythrocytes generated from SC15-
Cre2 iPSC clone. (D) Oxygen affinity curves of erythrocytes from SC15-Cre2 after terminal 










In this study, we developed a three-step differentiation system for efficient and 
reproducible erythrocyte production under a feeder-free and xeno-free condition. In the 
first step of HPC generation, we used a forced aggregation EB method to induce hiPSC 
differentiation, based on a pioneering study from Elefanty’s group in 2005 [169]. We and 
others have since improved this method. To develop a clinically applicable procedure, we 
evaluated critical reagents in terms of reliability and cost effectiveness. More 
importantly, we would introduce reagents that are already approved by FDA and 
available in pharmacy. We replaced unreliable sources of BSA by FDA-approved human 
albumin Plasbumin. These improvements gave much more consistent results in 
generation of HSPCs. The differences observed among hiPSC lines from different 
individuals may be largely due to genetic variations in the human population rather than 
the inconsistency of differentiation conditions. This finding and our experimental system 
should provide a platform to study genetic influences on erythropoiesis in the future. 
Using this method, we proved that the CRISPR/Cas9-mediated genome editing 
has little adverse effect on the integrity of targeted iPSCs, since they can differentiate into 
mature progeny such as enucleated erythrocytes that express the corrected HBB gene in 
SCD iPSCs. The level of HBB protein expression is similar to that of erythrocytes 
differentiated from untargeted iPSCs. Our study showing HBB protein expression in 
human erythrocytes differentiated from corrected iPSCs would not have been possible, if 
the HBB mRNA expression and protein synthesis had remained at low levels as 
previously observed [37, 147, 148, 188, 209, 217-219].  Previously, HBB protein 





vivo, unless transgene expression promoting erythroid formation [220-222] or co-culture 
with mouse stromal cell lines such as OP9 or MS5 were used [188, 192, 223].  Compared 
to these pioneering studies, we achieved much higher levels of HBB mRNA expression 
under the culture condition for producing erythrocytes generated from iPSCs such as 
TNC1 and their corrected progeny (Figure 4-4).  In addition, we also observed the 
presence of enucleated erythrocytes under the feeder-free and xeno-free culture 
condition, although the percentage was not high (typically 5-10%) compared to that 
derived from CB CD34+ cell cultures (30%-60%).    
The much improved erythrocyte maturation and HBB protein expression from 
hiPSCs that we reported here could be due to at least the following two possibilities, 
which are not mutually exclusive.  The first one is that we improved culture condition for 
terminal differentiation: we added human plasma that is known to promote enucleation, 
and omitted dexamethasone that promotes stressed erythropoiesis and fetal globin 
expression.  The second one is that we used blood-derived iPSCs that have some residual 
epigenetic memory inherited from parental cells (TNC1 was derived from peripheral 
blood erythroblasts and BC1 was from adult bone marrow hematopoietic cells).  This 
notion is also supported by a recent study showing that blood-derived iPSCs tend to have 
better erythroid differentiation potential than fibroblast-derived iPSCs [221].  Together, 
these studies provide additional strong evidence that residual epigenetic memory found in 
these blood-derived iPSCs [224-226] favors differentiation back to erythrocytes, 
especially when the differentiation condition is still sub-optimal.  According to this 
notion, blood MNC-derived iPSCs are a better choice for efficient erythroid 





earlier ones on the NIH registry).  This may explain the observations that in a previous 
study, erythrocytes generated ex vivo from fibroblast-derived iPSCs (in the presence of 
human plasma) did not produce sufficient levels of HBB proteins, until after they were 
infused to mice and matured further in vivo [190].  It is of note, however, that the 
fibroblast-derived iPSCs could generate enucleated cells and express the HBB proteins 
under enhanced conditions [190, 192], even though at an efficiency lower than that from 
blood-derived hiPSCs as we report here.  
Under the current culture conditions, however, the level of HBB expression (at 
both mRNA and protein levels) is still >10-fold lower than that of the HBG.  This may 
explain the fact that we and others did not observe sickling or defect in erythrocytes 
generated from hiPSCs derived from SCD patients [190].  The high-level of HBG protein 
may prevent the sickling of α2βs2 complexes, especially under culture conditions with a 
normoxic level of O2.   In the future, human differentiated erythrocytes generated ex vivo 
from hiPSCs (with or without genome editing) should be also tested in vivo using 
improved immune-deficient mice and conditioning [23], to examine in vivo properties of 
human erythrocyte in the circulation of the mouse models.  
For future therapeutic uses, it is desirable to correct at least one of the βs HBB 
allele in the iPSCs derived from SCD patients, before the iPSC-derived HPCs or 
erythrocyte can be used for autologous cell transplantation or transfusion.  In addition to 
achieving the elusive objective to develop a robust and reproducible method for 
generating transplantable HSPCs [150, 193], we could also use erythrocytes generated 
from patient-specific iPSCs, with or without genome-editing to correct the underlying 





hiPSC lines, which could be further irradiated to block DNA replication, may have less 
risk than other nucleated progeny in causing cancers [186, 187, 227].  We also envision 
that we could generate genetically modified erythrocytes from genome-engineered iPSCs, 
for providing a source of functionally enhanced erythrocytes for cell therapies, not just a 
source of replacement in transfusion medicine [187].  Future studies are warranted to test 
efficacy and safety of erythrocytes from genome-edited iPSCs in preclinical models and 
in clinical trials. 
4.5 Conclusion 
In this chapter, we developed an efficient and reproducible differentiation system 
to generate HSPCs from hiPSCs under a feeder-free and xeno-free condition, in which all 
the animal-derived products were eliminated. By replacing BSA with human albumin in 
EB differentiation and using human plasma in terminal maturation, we can consistently 
generate hiPSC-derived HSPCs and erythrocytes, showing enucleation and adult-
hemoglobin expression in gene-corrected iPSCs from SCD patients. The results discussed 









5 Scalable production of matured erythrocytes 
from hiPSCs 
 
In vitro production of erythrocytes in physiologic numbers from hiPSCs holds great 
promise for improved transfusion medicine and novel cell therapies. We report here, for 
the first time, a strategy for scalable and xeno-free differentiation of hematopoietic 
stem/progenitor cells from hiPSCs and subsequent erythrocytes specification, by using 
stepwise cell culture conditions and by integrating spinner flasks and rocker. This system 
supported robust and reproducible definitive hematopoietic differentiation of multiple 
hiPSC lines. We demonstrated an ultra-high yield of up to 4×109 CD235a+ erythrocytes at 
>98% purity when using a 1-liter spinner flask for suspension culture. Erythrocytes 
generated from our system can reach a mature stage with RBC characteristics of 
enucleation, β-globin protein expression and oxygen-binding ability. The entire process is 
xeno-free and clinically compliant, allowing future mass production of iPSC-derived 
RBCs for transfusion medicine purposes. 
5.1 Introduction 
In Chapter 4, we demonstrated a FA differentiation method in 96-well plates with 
modified xeno-free medium to provide robust and reproducible HSPC generation from 
hiPSCs [204], which can be used as a baseline for further improvement. For step (2) and 





hemoglobin-expressing erythrocytes using medium that contained EPO and human 
plasma [189-191]. However, the scalability of the differentiation system for erythrocyte 
production places a big hurdle for the large-scale manufacturing of HSPCs and 
enucleated erythrocytes for potential clinical applications. 
In this chapter, we aim to establish a scalable system that can support large-scale 
EB differentiation towards hematopoietic lineages and high-yield erythrocyte production 
from hiPSCs in vitro. To achieve this goal, we first sought to combine the expansion of 
undifferentiated hiPSCs and the formation of EBs in suspension using spinner flasks. 
Then we integrated this process with static and dynamic culture on a platform rocker to 
enhance the efficiency of HSPC generation. HSPCs differentiated in the scalable system 
were directly induced to generate mature erythrocytes in suspension in scalable settings. 
5.2 Materials and Methods 
5.2.1 EB differentiation in scalable vessels 
BC1 and TNC1 hiPSCs were expanded in 100-ml spinner flasks (CELLSPIN, 
Integra Biosciences) as cell aggregates in E8 medium (Essential 8, Thermo Fisher 
Scientific) as previously described [213] to yield a large quantity. Cell aggregates were 
dissociated into single cells by Accutase and inoculated at 4 × 105 cells/ml in spinner 
flasks at agitating speed of 35-50 rpm to initiate EB formation in 40 ml E8-based EB-
formation medium (E8-EB medium), which is E8 medium supplemented with 10 ng/ml 
BMP4 (R&D Systems), 0.5% w/v human albumin (Plasbumin-25, Amgen), and 10 µM 
ROCK inhibitor Y27632 (Stemgent). This was marked as day 0 of differentiation. On day 





medium with fresh E8-EB medium to remove dead cells. All medium was replaced by 
SFM-based EB differentiation medium [204] on day 2. On day 3, transfer the culture into 
a 150-cm2 tissue culture flask, and place in static (TS). After changing medium on day 6, 
put the tissue culture flask on a platform rocker at a frequency of 10-15 rpm (TR). 
Change ~70% of the medium on day 8, day 10, and day 13. Nplate (Amgen) were added 
at a final concentration of 20 ng/ml in EB differentiation medium from day 11 to day 13 
to enhance HSPC expansion. Single suspension cells were harvested on day 13 and 
sequentially cultured in erythroid differentiation medium that was also made xeno-free by 
replacing BSA with human albumin, with the same concentration of cytokines and holo-
transferrin for 10 days as previously described [189], followed by terminal maturation for 
6-8 days [189], in either TR or SF condition with low agitating speed. FA method (so 
called “spin-EB”) was applied as positive control as previously described [204]. When 
calculating yield, one batch of FA control was set as 8 plates of 96-well plates for the 
same 40-ml initial capacity. 
5.2.2 Erythroid differentiation and terminal maturation 
Suspension cells harvested from EB day 13 were directly transferred into 
erythroid liquid culture in tissue culture plates in static condition, on rocker, or in spinner 
flasks without the need of CD34+ isolation. The medium formulations for erythroid 
differentiation and terminal maturation were described previously [189, 205], except that 





5.2.3 Design and control of the DO level in glass-ball type spinner flasks 
DO level was monitored by a non-invasive optical O2 sensor probe using PreSens 
Oxy-4 Mini transmitter (PreSens). A sensor spot was attached to the inner wall of a 
spinner flask with silicon glue, and signal was detected by an optical probe from outside. 
We connected a gas cylinder containing 5% O2 + 5% CO2 + 90% N2 to the spinner flask 
and constantly flush 5% O2 at very low flow rate (~ 3 psi gauge pressure). A medium 
bottle was connected between the spinner flask and O2 cylinder, serving as both a heat 
exchanger for the influx O2 and the reservoir for pre-conditioned medium. Airtightness 
and flow was monitored by bubbling in a water bottle at the outlet of the spinner flask. A 
peristaltic pump was used to change medium and sampling during the operation without 
disclose the system to avoid re-oxidation. When changing medium, we stopped the 
agitation and allowed the cell aggregates or EBs to settle down to the bottom, then 
change approximately 70% of the medium. 
5.2.4 Morphological analysis using light microscopy and measurement of EB size 
Images were acquired using Eclipse TE2000-U microscope (Nikon). EB size was 
measured as previously described using Celigo imaging cytometer (Nexcelom). Data was 
collected from more than 450 EBs from three independent experiments. 
5.2.5 Fluorescence microscopy analysis 
After wash, images were acquired using Eclipse TE2000-U microscope (Nikon). 
5.2.6 RNA extraction and quantitative RT-PCR 
RNA extraction and RT-PCR analysis of globin genes HBB and HBG was 





genes, the primers were listed in the Table 5-1. All experiments were performed in 
triplicates, and a non-template control (no cDNA template) was included in each assay. 
Relative gene expression was normalized to the housekeeping gene GAPDH. 
Table 5-1. Primers for qRT-PCR 




























5.2.7 Western blot of HBB protein 
Western blot for HBB protein detection was performed using a monoclonal 
antibody against human HBB (Santa Cruz Biotechnology, sc-21757) and β-actin (Cell 
Signaling Technology, Cat. 3700P). The concentration of the protein extract from each 
cell samples was quantified using Pierce BCA Protein Assay Kit (Thermo Fisher 
Scientific) as per manufacturer’s instructions. Protein samples of iPSCs and iPSC-derived 
erythrocytes were loaded as 10 µg. 
5.2.8 Measurement of oxygen-hemoglobin dissociation curve 
Oxygen-hemoglobin dissociation curves of TM day 6 cells from scalable and 
unscalable conditions as well as primary cord blood control were measured using a 
Hemox Analyzer (TCS Scientific) as previously described [214]. 
5.3 Results 
5.3.1 The initiation of scalable EB formation in spinner flasks 
Utilizing our scalable expansion of undifferentiated hiPSC in suspension, which is 
matrix-independent and microcarrier-free [213], we transitioned to large-scale EB 
differentiation. Shear stress on hiPSCs in the suspension culture in agitating vessels is 
known to affect cell survival [122]. Medium flow in a spinner flask (SF) and a tissue 
culture flask on a platform rocker (TR) generate different levels of shear stress. Thus we 
first tested which scalable system better support EB formation from a single cell 
suspension from BC1 hiPSCs [11]. We found that the serum-free medium used in the 





support consistent bulk EB formation in suspension culture especially in spinner flasks, 
resulting in an unexpected high level of cell death with cell viability below 65% (Figure 
5-1, A). In contrast, EBs formed with a modified E8-based medium supplemented with 
human albumin and BMP4 in addition to the ROCK inhibitor Y27632 (called E8-EB 
medium thereafter) showed significantly higher cell viability, 89±4 % on EB day 1 
(Figure 5-1, A), demonstrating a simple but efficacious approach to enhance cell survival 
in spinner flasks during EB formation. We also found that EBs formed in the E8-EB 
medium in spinner flasks were more uniform in size, while many large EBs with irregular 
shapes formed on rocker likely due to insufficient and uneven agitation (Figure 5-1, B). 
Quantitative analysis of EB size indicated that EBs formed in spinner flasks have a 
homogeneous size with an average equivalent diameter of 187±36 µm, whereas a wider 
distribution of EB size was found on rocker (247±128 µm) with many compact EBs 
larger than 400 µm (Figure 5-1, C), which would cause cell death in the center due to 
insufficient transport of nutrient, waste and O2. Therefore, we chose to use E8-EB 
medium in spinner flasks as the optimized condition to form spatially and temporally 
synchronized EBs. Thus, we directly combined hiPSC expansion with EB formation in 







Figure 5-1. Optimization of initial EB formation in suspension cultures 
(A) Levels of cell viability on day 1 using different media for EB formation in suspension 
cultures. All media were supplemented with 10 µM Y27632 to promote cell survival. SFM-EB: 
serum-free medium with BMP4 and FGF2 as the medium used in the FA control of EB 
formation; E8-EB: E8 medium with BMP4 and human albumin (n = 3, mean ± SD). (B) 
Representative images of EBs formed at day 1 in spinner flask at 35 rpm (SF1) and 150-cm2 
tissue culture flask on rocker at 10 rpm on day 1 (TR1), respectively. Irregular shape and sizes 
were observed in TR day 1 EBs (scale bars = 1 mm). (C) Size of EBs at day 1 generated in 
spinner flask (SF1) or on rocker (TR1). More than 450 EBs in each condition from three 







5.3.2 Scalable generation of hematopoietic cells using an optimized integration of 
static culture and spinner flasks 
The yield from one bioreactor run (indicated as “batch yield”) is an essential 
parameter to measure outcomes in the scale-up process. In order to maximize the yield of 
the EB differentiation, we explored several strategies using SF and TR (Figure 5-2, A), 
based on media and timeline modified from the FA method previously established [204]. 
After formed in spinner flasks, EBs harvested on day 3 were cultured either in spinner 
flasks or on rocker. In one condition, a 3-day static culture in tissue culture flasks (TS, 
see illustration in Figure 5-2, A) was also applied between the spinner and the rocking 
condition (SF-TS-TR). We compared the yield of suspension cells released from EBs 
(harvested at day 13) in batches with 40-ml initial volume followed by different 
combinations of these module conditions (Figure 5-2, A). From four independent 
experiments in each condition, the conventional FA method generated 10.2±4.2×106 live 
cells from eight 96-well plates starting from 40-ml of initial single cell suspension 
(Figure 5-2, B). Among the strategies in scalable settings, the methods in which EBs 
were in free suspension throughout the culture (such as SF, TR and SF-TR, see Figure 5-
2, A) showed poor reproducibility with about 50% of experiments failing to generate 
hematopoietic cells. Only the combinatorial SF-TS-TR strategy including a 3-day static 
culture in tissue culture flasks supported more consistent differentiation with higher 
yields. A total of 29.1±10.8×106 live cells were generated from SF-TS-TR suspension, 





Figure 5-2. Establishment and optimization of a scalable protocol for hematopoietic 
cell generation in suspension 
(A) Schematic presentation of strategies for scalable EB differentiation and production of hiPSC-
derived erythrocytes. The differentiation was induced in three successive steps: embryoid body 
differentiation (EB), erythroid differentiation (ED) and terminal maturation (TM). Media and 
culture condition changes are illustrated according to the timeline of differentiation. (B) Yield of 
single suspension cells on day 13 from one batch using different EB differentiation protocols. SF 
and TR represent continuous EB differentiation for 13 days in spinner flasks and tissue culture 
flasks on rocker, respectively. SF-TS or SF-TR represent additional 8 days in static or rocking 
condition, respectively, after 3-day EB formation in spinner flasks (n = 4, mean ± SEM). (C) 
Exemplary light microscopy images of EB differentiation using SF-TS-TR on day 6 and day 13. 
EB attachment on day 6 and single hematopoietic suspension cells on day 13 were clearly shown 
(scale bars = 200 µm). (D) Batch yield of total single suspension cells from 40-ml cultures using 
different SF-TS-TR strategies with static culture for 1 day (TS1), 2 days (TS2) and 3 days (TS3) 
(n = 3, mean ± SD). (E) Expression of KDR, GATA2, RUNX1, MYB and HHEX genes in EB cells 
from continuous agitating SF or SF-TS strategies on EB day 6 (normalized to endogenous 
GAPDH as a housekeeping control; n = 2 independent experiments with 3 technical replicates 










Next, we investigated the potential mechanisms underlying the improvement in 
yield when using SF-TS-TR strategy. The three days of static culture was the only 
difference between SF-TS-TR and SF-TR. Light microscopy images revealed 
distinguishable changes of EB morphology and confirmed the emergence of HSPC on 
day 13 (Figure 5-3 and Figure 5-2, C). Under the FA condition, EBs formed after 2-3 
days of centrifugal aggregation appeared loosely attaching to the bottom of the well (even 
in low-attachment or untreated plates). Cystic structure inside EBs emerged on or around 
day 5, indicating the embryonic development and cell differentiation (Figure 5-3). In SF-
TS-TR method, hiPSCs formed more homogenous EBs in size on day 2 compared to FA 
or SF-TR (Figure 5-3). Three days in static condition provided the environment for the 
EBs to loosely attach to the bottom of tissue culture flasks (Figure 5-2, C), similar to the 
FA method compared to completely free floating EBs in SF-TR. It was clear that the 
three days of static culture was beneficial for a high yield of hematopoietic cells in 
suspension on day 13 when compared to 2-day or 1-day static culture (Figure 5-2, D). 
After three days in static condition, genes associated with mesoderm commitment and 
hemato-vascular lineages were all elevated (Figure 5-4).  As a result, cells through the 3-
day static condition showed significantly higher expression of key genes related to 
mesoderm formation (KDR) [194], hemato-vascular development (GATA2 and RUNX1) 
[197, 228] and definitive hematopoiesis (MYB and HHEX) [220, 229, 230] compared to 
cells from suspension EB differentiation in spinner flasks (Figure 5-2, E).  This is in line 
with the higher hematopoietic yield from cultures with 3-day in static condition in 





       
 
Figure 5-3. Morphology analysis of the scalable EB differentiation protocols 
Low magnification images show the morphology of the whole EBs in different methods on day 2, 
day 5 and day 13. FA indicates forced aggregation EB control, SF-TR indicates the differentiation 
contains 3 days of EB formation in spinner flasks followed by 10 days of continuous suspension 
culture in tissue culture flasks on platform rocker. SF-TS-TR indicated 3 days in spinner flasks 
followed by 3 days in static condition in tissue culture flasks and 7 days of rocking culture (scale 






Figure 5-4. Gene expression profile of whole EB cells from continuous spinner flask 
and SF-TS conditions on EB day 3 to EB day 6 
EBs were differentiated in spinner flasks for 2 days in E8-EB medium and 1 day in serum-free 
differentiation medium. TS1 means 1 day in T150 flask in static condition after 3 days in SF, and 
so on. Gene expression was normalized to endogenous GAPDH as a housekeeping control (n = 2 
independent experiments with 3 technical replicates each, mean ± SD). 
 
 
5.3.3 Characterization of single cells from scalable EB differentiation 
Similar to the FA control, suspension cells harvested from SF-TS-TR at EB day 
13 contained 75.6±12.3 % CD34+ cells and 64.2±11.9 % CD34+CD45+ cells, with little 
erythrocytes that should express CD235a (Figure 5-6, A). The batch yield of 
CD34+CD45+ cells from SF-TS-TR was 14.6±4.5×106, which was significantly higher 





level of hematopoietic progenitor cells in the total and CD34+ purified suspension cell 
populations (Figure 5-6, C). These results indicated that the CD34+CD45+ cells generated 
from SF-TS-TR had comparable contents of myeloid and erythroid progenitor cells as the 
FA method. 
5.3.4 Erythroid differentiation and terminal maturation in a scalable system 
Considering that >70% of the suspension cells were CD34+ cells, we found that it 
was not necessary to isolate CD34+ cells for downstream erythroid production under a 
culture condition selectively favoring erythroid cell proliferation and differentiation. 
After EB formation and initial hematopoietic differentiation (Figure 5-2, A), single cells 
were harvested at day 13 by passing the entire culture through a 40-µm cell strainer and 
immediately transfer to the following differentiation steps. This simple “filter-and-go” 
process would be highly favorable for the scale-up bioprocess. Previous studies found 
that even mild agitation at 15-20 rpm in stirred tank bioreactor had significant impact on 






Figure 5-5. Characterizations of differentiated hematopoietic cells derived from 
hiPSCs using the SF-TS-TR protocol 
(A) Representative flow cytometric analysis of CD34, CD45, and CD235a in the suspension cell 
populations harvested on EB day 13. Gates were set based on corresponding isotype controls. (B) 
Quantification of the batch yield of CD34+, CD45+, and CD34+CD45+ cells from SF-TS-TR 
method (n = 4, mean ± SD). (C) CFU assays of total suspension cells and anti-human CD34-bead 
isolated suspension single cells from SF-TS-TR method. After isolation, >95% of the cells 
showed CD34+ by flow cytometric analysis. The total number of CFU was analyzed by the two-








We also confirmed that shear stress generated by agitation at medium speed range 
(40-50 rpm) in spinner flasks impeded the expansion rate of erythroid expansion and 
differentiation (Figure 5-7, A). By reducing the agitation to low speed range in SF (22.5 
rpm) or TR at low rocking frequency (10-15 rpm), expansion in erythroid differentiation 
(ED) and terminal maturation (TM) were recovered and comparable as the static culture, 
calculated at 211±22 fold and 237±56 fold increase, respectively (Figure 5-7, A). The 
entire process in scalable system yielded 3.2±0.6×109 CD235a+ erythrocytes, 1.5-fold 
higher than those from the FA control (Figure 5-7, B). After scale-up to 1-liter spinner 
flasks, we achieved an ultra-high yield of 4.1×109 hiPSC-derived erythrocytes from a 40-
ml SF-TS-TR batch. Taking these steps together, we established a complete procedure for 
the scalable production of human erythrocytes through EB formation (Figure 5-2, A). A 
cell suspension containing 1×109 cells in 10 ml PBS showed red color like diluted blood 






Figure 5-6. Scalable erythroid differentiation and terminal maturation of the 
suspension cells from SF-TS-TR protocol 
(A) Optimization of the agitating speed in scalable platforms for ED-TM using the suspension 
cells from SF-TS-TR by analyzing accumulated expansion fold increase (n = 3, mean ± SD). All 
of the other conditions were significantly higher than SF 40 rpm condition (P < 0.05). (B) 
Calculated batch yield of CD235+ erythrocytes on day 6 of terminal maturation (TM6) from 
suspension cells generated by FA or SF-TS-TR EB and through scalable ED-TM in TR at 10 rpm 
and/or SF at 22.5 rpm (n = 4, mean ± SD). (C) Image of 1 × 109 TM6 cells in 10 ml PBS. Cells 
were from 1/3 batch of scalable production of hiPSC-derived erythrocytes. (D) Representative 
flow cytometry data reveals the progressive changes of phenotype during ED-TM. All gates were 
set based on corresponding isotype controls. (E) Representative flow cytometry analysis of 
enucleation rate of TM6 cells using DRAQ5 staining for nuclei. All gates were set based on 
corresponding isotype controls. (F) Representative fluorescent images of TM6 cells generated 
from SF-TS-TR EB and scalable ED-TM. Solid arrows indicate live and metabolic active 
enucleated erythrocytes that were double stained by CD235a and Calcein AM but lack of nuclei 
and DRAQ5-staining of DNA. Triangle arrowheads indicate separated nuclei after enucleation, 
known as pyrenocytes. White open arrows indicate pieces of broken cell membrane that were 
only stained by CD235a (scale bar = 20 µm). (G) Wright-Giemsa (for cytoplasm and nuclear 
DNA) and benzidine (for hemoglobin) staining of TM6 cells from scalable production. Most of 
the nucleated cells showed morphology of orthochromatic erythroblasts that contained 
hemoglobin (brown color by benzidine staining). Arrows indicate enucleated erythrocytes, and 











Phenotypic changes in the suspension cells from SF-TS-TR during the scalable 
ED-TM steps were tracked by flow cytometry (Figure 5-7, D and 5-8). Plots of forward 
scatter and side scatter showed the shrinking in size of erythroblasts during the 
maturation period (Figure 5-8, A). The gradual loss of CD45 and gain of CD235a 
expression indicated the loss of multipotent HSPCs and myeloid cell populations, and 
enrichment of erythroid population (Figure 5-7, D). When we analyzed the expression 
patterns of two erythroid stage-specific markers Band3 and CD49d (alpha4 integrin), we 
also observed a rapid and synchronized erythroblast maturation process from 
CD49d+Band3-, to CD49d+Band3+, and then to CD49d-Band3+, in line of previous 
studies using primary CD34+ cells or hiPSCs under the FA condition [189, 232]. After 6 
days in TM culture, more than 95% of the cells were CD45-CD235a+Band3+CD71+. Only 
a few cells (0.5%-1.5%) expressed markers of myeloid lineages such as CD14, CD41, 
CD42a, CD15 and CD33 (Figure 5-8, B) and no cells express lymphoid markers (data not 
shown). These data collected a highly pure population of erythrocytes as early as day 6 of 
TM. Enucleation (removal of nuclei) rate was measured by staining DNA with DRAQ5, 
followed by flow cytometry (Figure 5-7, E). Erythrocytes from SF-TS-TR showed 2.8%-
11.1% of enucleation rates from multiple experiments, similar to the same batch of FA 
control group and the range of variation. The enucleated cells remained metabolically 
active and with intact cell membrane (Figure 5-7, F) and expressed hemoglobin protein 






Figure 5-7. Flow cytometry analysis of ED-TM cells from scalable EB differentiation 
(A) Representative flow cytometry dot plots of forward scatter (FSC) and side scatter (SSC) of 
cells during ED-TM from SF-TS-TR condition. Red circles indicate the mixture of pyrenocytes 
and cell debris. (B) Representative flow cytometry dot plots of additional markers for different 










5.3.5 Robust and reproducible generation of erythrocytes from hiPSC lines 
In order to test the robustness and reproducibility of the scalable differentiation 
system, we repeated the process in two other hiPSC lines (TNC1 and E2) using the same 
SF-TS-TR protocol. TNC1 was derived from human erythroblasts that were established 
from the peripheral blood mononuclear cells of a sickle cell disease patient, while E2 was 
derived from human mesenchymal stem cells that were established from the bone marrow 
mononuclear cells of a healthy donor. Both lines accomplished efficient and high-yield 
generation of HSPCs, erythroblasts and erythrocytes (Table 5-2 and Figure 5-9), 
confirming the robustness and adaptability of the scalable differentiation system. 
 
Table 5-2. Summary of the yield in three hiPSC lines at the end of each 
differentiation steps from the scalable system 
hiPSC 
Lines 
Yield (×106 ) from 40-ml of EB differentiation using SF-TS-TR (n = 3) 
 EB13 ED10 TM6 
 CD34+CD45+ CD36+CD235a+ CD235a+ Enucleated 
BC1 17 ± 5 843 ± 366 3947 ± 418 385 ± 206 
E2 12 ± 4 653 ± 82 3928 ± 1017 206 ± 161 







Figure 5-8. Flow cytometry analysis on TNC1 and E2 iPSC-derived HSPCs, 
erythroblasts and erythrocytes using the scalable strategy 
Representative flow cytometry dot plots of the expression of critical markers on EB day 13, ED 
day 10 and TM day 6 of the differentiation of TNC1 iPSCs. An image of cytospin slide of TM6 
cells stained with Benzidine and Giemsa also indicates efficient enucleation and saturation of 





5.3.6 Hemoglobin expression and oxygen carrying function of the erythrocytes 
generated from the scalable system 
We analyzed the expression of hemoglobin genes particularly β-globin gene at 
both mRNA and protein levels. The mRNA level increased dramatically along the 
differentiation. On TM day 7, cells from SF-TS-TR showed similar mRNA level of HBB 
and HBG as erythrocytes derived from cord blood CD34+ cells that were induced ED-TM 
in the same medium and scalable settings (Figure 5-10, A). We further found that ~64% 
of TM day 7 cells from SF-TS-TR contained β-globin, while nearly 100% of the cells 
expressed γ-globin (Figure 5-10, B). These cells produced β-globin in the similar level as 
those from FA (Figure 5-10, B-C). 
We also determined whether the hemoglobin in the cells was functional to bind to 
O2 molecules at high concentration and release them at low concentration. Oxygen-
hemoglobin dissociation curve of BC1-derived erythrocytes in scalable settings were 
measured and found to be similar to the curve of primary cord blood RBCs (Figure 5-10, 
D). Interestingly, TM day 6 cells from SF-TS-TR method (P50 = 19.2 mmHg) showed 
lower O2 binding affinity than those from FA method (P50 = 16.1 mmHg), and were 
closer to cord blood (P50 = 24.0 mmHg). It is known that fetal hemoglobin has a higher 
affinity to bind to O2 and cord blood express both fetal and adult hemoglobin. This result 
is consistent with the data that the content of fetal hemoglobin in the erythrocytes from 







Figure 5-9. Hemoglobin expression and oxygen binding function of hiPSC-derived 
erythrocytes from scalable production 
(A) Quantitative RT-PCR analysis of HBB and HBG gene expression in the cells generated from 
unscalable (FA EB to static ED-TM, marked as FA Control) and scalable strategy (SF-TS-TR EB 
to dynamic ED-TM, marked as SF-TS-TR) at different stages, including undifferentiated iPSCs, 
total suspension cells after EB differentiation day 13 (EB13), erythroid differentiation day 10 
(ED10) and terminal maturation day 7 (TM7). Erythrocytes derived from cord blood CD34+ cells 
(CB CD34+) following the same ED-TM conditions were analyzed together as a control 
(normalized to endogenous GAPDH as a housekeeping control; n = 2 independent experiments 
with 3 technical replicates each, mean ± SD). (B) Representative flow cytometry plots of 
intracellular adult and fetal hemoglobin protein in TM7 cells. (C) Western blot analysis of human 
adult β−globin (HBB) protein. BC1 iPSCs and TM7 cells from FA EB and two independent runs 
of SF-TS-TR EB were loaded as 10 µg total protein. β-actin was stained as a housekeeping 
control. (D) Oxygen-hemoglobin dissociation curves of TM7 cells from scalable method (SF-TS-







Along with the flourish of transformative hiPSC technologies, cell culture 
conditions for scalable expansion of undifferentiated hiPSCs have been improved 
significantly [112, 113, 115, 122]. Chemically defined, feeder- and xeno-free culture 
media and substrates are able to support long-term and scalable expansion of hiPSCs 
while keeping a normal karyotype as we have demonstrated [233]. These improvements 
suggest a bypass to the elusive goal of ex vivo expansion of human HSPCs, especially 
long-term stem cell activities, which remains challenging even with primary 
CD34+CD45+ cells [145]. Therefore, one can expand undifferentiated hiPSCs first into a 
large number, followed by a large-scale and high-efficiency differentiation process of 
HSPC production, to achieve a high yield of a final blood cell product such as 
erythrocytes. During this multi-step differentiation process, the generation of HSPCs 
from hiPSCs that are able to generate multiple types of mature hematopoietic cells is the 
rate-limiting step [193]. In the current study, we demonstrated the first complete 
procedure for scalable production of erythrocytes from hiPSCs under a feeder-free and 
xeno-free culture condition, with the innovation of EB differentiation integrating spinner 
flask and rocker. 
The current success was based on our previous study where we demonstrated that 
hiPSCs can form cell spheres of an average equivalent diameter of ~200 µm in spinner 
flask culture under an optimized speed in E8 medium [213].  Each sphere contains 
approximately 3,000 cells, which correspond to the optimized number of input hiPSCs to 
form one EB per well in the FA EB formation method. For the EB formation in 





checkpoint for differentiation efficiency, because apoptotic or dead cells wrapped inside 
the EBs would lead to break or failure of EB formation. Single cells of hiPSCs seeded on 
day 0 were most vulnerable to shear-induced cell death, whereas insufficient shear would 
also cause agglomeration and lead to transfer deficiency of O2, nutrients and metabolic 
wastes. Therefore, we sought to find a balance by choosing the appropriate platform and 
optimizing the agitating speed and culture medium formulation for EB formation in the 
critical first two days. We also found that different hiPSC lines had distinct sensitivity 
and tolerance to shear stress in spinner flasks, indicated by cell survival and EB sizes.  
Some hiPSC lines such as BC1 and E2 survived poorly in spinner culture with the SFM-
EB medium, even in slow agitation. In contrast, we reported here that a new EB 
formation medium based on the original E8 medium significantly enhanced the cell 
survival. Moreover, we observed that physiological O2 tension (5%) that was known to 
enhance hiPSC survival also enhanced EB formation and differentiation, using an oxygen 
monitoring and controlling system (Figure 5-11). It was reported that the dissolved O2 
level in the media affected the rate and maturation of erythroblasts in vitro [234].  This 
oxygen monitoring and controlling system would also provide a suitable apparatus for 







Figure 5-10. Design of an oxygen monitoring and controlling system for glass-ball 
type spinner flasks 
(A) Schematic illustration of the design. Red lines indicate liquid channels, while blue lines 
indicate air flow path. (B) Pictures of system settings inside and outside the incubator. (C) 
Prolonged control of dissolved O2 in the medium real-time monitored by non-invasive probe. (D) 
Cell density increase on day 3 of iPSC culture in E8 medium as cell aggregates in 5% O2 
compared to 20% O2 (n = 3, mean ± SD). (E) Cell viability of BC1 cells on EB day 1 in SFM-EB 
differentiation medium (SFM+BMP4+bFGF) (n = 3, mean ± SD). 
 
 
Shear stress induced by agitation is also known to play an important role in iPSC 
differentiation [235, 236]. The glass-ball type spinner flask produces laminar flow (Re < 
1000) and mild shear rate less than 0.15 N/m2 [213], while tissue culture flasks on a 





approximately 0.01 N/m2 measured in previous studies [237]. A static condition causes 
no shear on EBs. Compared to the freely floating EBs in a continuous suspension 
condition, the stepwise SF-TS-TR procedure showed higher differentiation efficiency and 
reproducibility. The enhancement may be due to the static condition and the loose 
attachment of EBs to the surface of cell culture vessels. This semi-adhesion might 
provide better environment for the generation of hemogenic endothelial cells and 
strengthened the up-regulation of many critical genes related to mesodermal and 
hematopoietic development such as KDR, GATA2, RUNX1, HHEX and MYB [228]. The 
mild agitation on a rocker in the following step might be beneficial for the hematopoietic 
differentiation by enhancing transport and preventing complete attachment leading to loss 
of EB structures. The CD34+CD45+ cells generated from the SF-TS-TR procedure appear 
to be definitive hematopoietic progenitor cells because they can form multiple types of 
myeloid cells and erythrocytes that express HBB and mature to enucleated cells. The 
suspension cells harvested at EB day 13 enriched for CD34+CD45+ cells contained few 
CD235a+ cells before EB day 13, the early onset of which was suggested to be an 
indicator of primitive hematopoiesis independent of CD34+CD45+ HSPC formation 
(Kennedy et al., 2012).  
The SF-TS-TR method requires 8.3-fold more input of hiPSCs per run than the 
FA method to initiate EB differentiation in current settings, which causes about 3-fold 
decrease in the efficiency of CD235a+ erythrocyte generation per input hiPSC on TM6. 
However, the batch yield is still about 2-fold higher. More importantly, the scalability of 
the SF-TS-TR system enables a volumetric scale-up process, which is more preferable in 





By one batch of hiPSC differentiation, we generated 4.1×109 CD235a+ erythrocytes using 
1-liter spinner flasks at a density of approximately 4×106 cells/ml. Therefore, it is 
possible to produce sufficient erythrocytes for a clinical unit of blood (containing 2×1012 
RBCs) from one batch of 500-liter stirred tank bioreactor or WAVE bag bioreactor. 
Although reducing the cost remains a challenge of ex vivo generation of transfusable 
RBCs from hiPSCs [151], the concept and improvement demonstrated in our study is an 
important step forward leading to a feasible solution of reducing manufacturing cost by 
expanding production scale. 
The HSPCs generated from this scalable system were confirmed to exhibit 
comparable phenotype and potential for multi-lineage differentiation as the HSPCs from 
the FA method that were extensively evaluated in the previous studies [189]. Despite the 
substantially increased contents of functional hemoglobin, the enucleation rate (2%-15%) 
we achieved so far was still low as compared to those derived from primary 
CD34+CD45+ cells (≥30%), and varied between hiPSC lines and from batch-to-batch to 
certain degrees.  
5.5 Conclusion 
In summary, we generated erythrocytes from three hiPSC lines in a scalable 
differentiation system that combined spinner flask and rocker for EB differentiation, 
erythroid differentiation and terminal maturation. We achieved high batch yield, β-globin 
expression and complete terminal maturation in the hiPSC-derived erythrocytes in a 
scalable setting. This work provides a feasible solution for large-scale production of 





6 Conclusion and Suggestions for future study 
 
6.1 Conclusion 
Large-scale ex vivo generation of matured RBCs for transfusion purpose from 
hiPSCs holds great promise to fulfill the unmet global demand of blood transfusion. In 
this thesis we improved the current technologies for the expansion and hematopoietic 
differentiation towards erythrocytes from hiPSCs, and established scalable systems using 
spinner flask and rocker platform with the consideration of clinical compliance and large-
scale manufacturing. 
In Chapter 3, we described the establishment of a reproducible approach for rapid, 
economic, and scalable expansion of hiPSCs in xeno-free condition using spinner flask to 
meet the demand of practical research and clinical applications. The hiPSCs were 
maintained in dynamic suspension culture as cell aggregates for more than 20 passages 
with a consistent expansion rate, well-preserved pluripotency and normal karyotype. In 
Chapter 4, we described the development of an efficient and reproducible differentiation 
system to generate HSPCs from hiPSCs under a feeder-free and xeno-free condition in 
which all the animal-derived products were eliminated. We further generated hiPSC-
derived HSPCs and erythrocytes, showing enucleation and adult-hemoglobin expression 
in gene-corrected iPSCs from SCD patients. In Chapter 5, we demonstrated an improved 
scalability of the differentiation system by applying the combination of spinner flask and 





terminal maturation in the hiPSC-derived erythrocytes. Our work sheds light on the 
critical effects of physical conditions during in vitro hematopoiesis of hiPSCs. The ease 
of operation, the simplicity of cytokine combination and the high level of chemical 
definition of the components added favorable features to this system in a scale-up point 
of view. Furthermore, because all the components used in our system for the entire 
expansion and differentiation process are formulated with recombinant human proteins, 
FDA-approved biologics, or materials from human sources, this xeno-free and cGMP-
compliant system provides the opportunity to produce clinical-grade erythrocytes from 
hiPSCs in a large-scale bioprocess. Therefore, this study is a significant step towards the 
goal of large-scale generation of RBCs for therapeutic purposes. 
6.2 Suggestions for future study 
The methods for expanding hPSCs have improved significantly in recent years, 
facilitating robust and scalable clinical-grade hPSC production. Current knowledge of 
synthetic surfaces and suspension culture systems will likely continue to progress. More 
ready-to-use, chemically defined and xeno-free culture systems for culturing hPSCs using 
cGMP will follow the development of a deeper understanding of the chemical and 
biological mechanisms related to hPSC self-renewal. More studies of adhesion culture 
systems should focus on the optimization of different combinations of synthetic surfaces 
and xeno-free serum-free media with only small molecule cocktails to get preferable 
culture systems that can widely used to support for the expansion of a broad range of 
hPSC lines. These culture systems should also be tested for their capability of supporting 





hPSCs at full production scales — for example, tens or hundreds of liters — will benefit 
from better understanding questions at scales ranging from millimeters (microcarrier 
engineering) to tens of meters (large bioreactor design). For MC-based culture systems, a 
synergetic development of synthetic surface technologies and microcarrier design (i.e. 
size, shape, porosity, etc.) may result in favorable microcarriers for hPSC expansion. 
Systematic optimization of seeding and feeding strategies could also help to overcome 
the hurdles of bad attachment and undesired agglomeration in large-scale bioreactors. For 
aggregate-based suspension culture, optimization of media composition, operation 
protocol, and bioreactor structure should be given the highest priority to ensure good 
formation and maintenance of the cell aggregates during a scale-up process. All 
developed systems should be tested for their capability to sustain high pluripotency, and 
the phenotypic, genetic, and epigenetic stability of multiple hPSC lines. More 
importantly, successful development of high-efficient differentiation protocols to desired 
cell types is really the rate-determining step. Differentiation with high efficiency in 
feeder-free and defined conditions should be an ultimate goal for the study on hPSC fate 
commitment. Using one or multiple hPSC-derived cell types to generate functional 
engineered tissue will take another leap to reach a whole new level of cell therapies. We 
can expect that, combined with other advances in derivation and differentiation 
technologies, more clinical trials using hPSCs and their progenies will be approved in the 
near future, working to reach the next generation of stem cell therapies.  
The other aspect that needs to be further improved is the low enucleation rate. 
Although some studies suggested that the erythroblasts generated in vitro could 





reach full enucleation and eliminate all nucleated cells before being transfused into 
recipients. More efforts are needed to further improve the enucleation of hiPSC-derived 
erythrocytes. Recent reports on transcription profile of enucleating erythroblasts derived 
from cord blood CD34+ cells [232] and hESCs [239] provide an insight in the molecular 
signature of the enucleation process and may lead us to find more efficacious solutions to 
improve enucleation in suspension culture conditions. 
Furthermore, the scalability of the current differentiation system is still not ideal, 
largely due to the inclusion of a static culture step. Although completely suspension 
conditions were reported successful for the differentiation of other cell types, such as 
cardiomyocytes and neural progenitor cells [152, 154-156], the production of 
mesodermal lineages seems encountered more challenges. More work needs to be done 
for a better understanding of the hematopoiesis niche and the interaction between 
hematopoietic progenitor cells and surrounding stromal cells in vivo [240]. Other studies 
focusing on the development of novel bioactive materials and scaffolds [241-243] may 
also shed light on the construction of appropriate micro-environment that supports better 
HSPC and erythrocyte generation. 
Finally, better animal models for the study of stem cell-based transfusion 
therapies needs to be established before more comprehensive clinical studies in human. 
We have been using the NSG mice to conduct in vivo studies.  However, others and we 
encountered technical hurdles that remain challenging to all the investigators in the field. 
Current mouse models are not optimal at all to test in vivo functions of mature human 
RBCs in the circulation.  Typically, a very low percentage (<1%) of circulating RBCs are 





RBCs in the previous studies [238].  It is widely believed that the mouse Mononuclear 
Phagocyte System (also called Reticuloendothelial System or Macrophage System) 
recognizes human RBCs as xenoantigens and destroys human RBCs, even in the NSG 
mice lacking functional T, B and NK cells [244].  Various approaches are in development 
to better demonstrate the presence and circulation of human mature RBCs in mouse 
models.  More tests should be done focusing on the nucleated and enucleated 
erythrocytes (that we now can make in large quantity) in improved mouse models with 
various conditioning treatments, such as reducing macrophage activities by using 
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